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Abstract
A novel approach that has generated amide bond cleaving catalytic antibodies
is described. In this approach, the use of phenol as an auxilliary nucleophile was
coupled with the heterologous immunization protocol for potential generation of bi-
functional antibody binding sites. Three haptens were designed and synthesized;
two of these were used as an immunogen-pair in heterologous immunization, and
also individually in homologous immunizations. One antibody from each
immunization protocol was found to effect the cleavage of p-nitroaniline propionate
87 in the presence of phenol. Detailed kinetic studies of these antibody catalysts
are presented. Significantly, all three antibodies required the participation of
phenol for catalytic activity while the addition of phenol had no effect on the rate of
the background reaction. These results point to the power of nucleophilic catalysis
that had previously not been harvested for antibody catalysis. Possible future
applications of this approach to reactions other than amide hydrolysis are discussed
at the end of this account.
Thesis Supervisor: Professor Satoru Masamune
Title: Arthur C. Cope Professor of Chemistry
We live, as we dream - alone.
- Joseph Conrad,
The Heart of Darkness
Everything is miraculous. It is miraculous that one
does not melt in one's bath.
- Pablo Picasso
"Every act of creation
is preceded by a period of confusion."
This thesis is dedicated to my cat Hanno
the most perfect creature I have known in my life,
who has been with me through the hardest
and the happiest moments of these six years,
and who has always known when:
'to bite me, when I wanted to be bit,
and lick me, when I wanted to be licked.'
very few people will ever realize the subtlety...
Acknowledgements
First and foremost, I would like to express my gratitude to my thesis advisor,
Professor Satoru Masamune, for the extraordinarily high standards of research he
has maintained in his research group that has made me grow as a scientist, and
also for his kind persona. I take an enormous pride in being a "Masamune-student".
I am also grateful to Professor Anthony J. Sinskey, in whose labs the
biological portions of this project were realized, and who always had a fresh
perspective to offer on research in science.
Thanking can not be sufficient to display my appreciation of the efforts of Mr.
Roman Fleck; in addition to performing a significant portion of the work that is
summarized in Chapter 3, he was often the bearer of the brunt of my frustrations,
adding a level of sanity and continuity to this project. I wish him the best of luck for
the rest of his tenure at MIT.
Two colleagues stand out as my early sources of encouragement in the
Masamune Labs. Dr. Simon F. Williams supplied with me with indispensable lift
when my scientific wings were still too wet to open, and Dr. Hiro Suga served an
extraordinary course of intellectual nourishment, as well as well-timed motivation.
I shudder to think where I would be without their help.
A number of colleagues also added to my experience in Masamune Labs,
chiefly Dr.'s Thomas Jaetsch, Sandra Filla, Lian-Yong Chen, Emma Parmee and
Takeshi Tsumuraya. I send them my heartfelt thanks.
I would also like to extend my appreciation and thanks to the staff of the
Chemistry Headquarters, especially M.T. Kuo, Susan Brighton, Kitty Valleli and
Marian Curley, for their competence, friendliness and helpfulness. I thank Dr.
Kristin Rosner for her critical reading of this thesis, and of course, Janet
McLaughlin for her excellent job in keeping the Masamune group in working-order.
These six years would have not passed without the wonderful companionship of
Mr. Peter H. Lorenz, my dearest friend, co-reign in Boston, and a candidate for Ph.D.
degree in International Relations at Boston University. Thank you, my "Manda"!
The Kuemmerle family; Amy, Lou-Beth, Fred, Jill, Patty and of course, "Gramms",
has been my home away from home for nearly all of my ten years in the United
States. The warmth of your love I will carry with me no matter how far I travel.
Finally, a word of thanks to the city of Boston for all the cultural stimulation
it has offered me to develop my personality, intellect and general awareness; of
others, as well as myself. I will surely miss my days and nights in this city. Some
thanks are also due to the city of New York for helping me keep in mind that there
is always something better. As Rimbaud said; "Life is Elsewhere"...
Table of Contents
Chapter 1: Introduction.............................................................................. 10
Chapter 2: Background ............................................................................... 17
2.1 Phosphate, Phosphonate and Phosphinate based Haptens .......... 17
2.1.1 Regioselective Ester Hydrolysis by Catalytic Antibodies 18
2.1.2. Enantioselective Ester Hydrolysis by Catalytic
An tibodies.................................................................................... 19
2.1.3 Cocaine Degradation by Catalytic Antibodies .................. 22
2.1.4 Pro-drug Activation by Catalytic Antibodies.................... 23
2.1.5 Investigations of Amide Hydrolysis by Catalytic Antibodies
Raised to Phosphonate Haptens ................................................ 25
2.2 Second Generation Haptens Based on Antigen-Antibody Charge
Complementarity or Metal co-factors ................................................... 29
2.2.1 Pyridinium Alcohol Haptens for the Antibody Catalyzed
Hydrolysis of Benzoate Esters ................................................... 30
2.2.2 Esterolytic Antibodies Induced to Haptens with a 1,2-
Amino Alcohol Functionality...................................................... 31
2.2.3 Metal Based Haptens to Generate Amidase Antibodies. 33
2.3 Third Generation Hapten Design: Heterologous Immunization.. 35
2.3.1 Original Antigenic Sin ....................................................... 36
2.3.2 Esterolytic Antibodies Generated by Heterologous
Im m unization .............................................................................. 38
2.4 Fourth Generation of Haptens: Combination of Heterologous
Immunization with Nucleophilic Catalysis .......................................... 40
2.4.1 A Brief Synopsis of Proteolytic Enzymes .......................... 41
2.4.2 Mechanistic and Structural Studies of Acyl Hydrolyzing
An tibodies.................................................................................... 42
2.4.3 R em arks ............................................................................. 47
Chapter 3: Catalytic Antibodies for Amide Hydrolysis ....................... 49
3.1 Introduction ..................................................................................... 49
3.2 H apten D esign ................................................................................. 49
3.3 Synthesis of Haptens, Inhibitors and Substrates .......................... 52
3.4 Homologous and Heterologous Immunizations ............................. 55
3.5 Fusions and Generation of Hybridomas ....................................... 56
3.5.1 Homologous Immunizations .............................................. 56
3.5.2 Heterologous Immunizations ........................................... 57
3.6 Antibody Production and Purification............................................ 57
3.7 Amide Hydrolysis Assay with Unimolecular Substrate 75........... 59
3.8 pH -optim um Studies ....................................................................... 61
3.9 Cleavage of Propionyl p-Nitroanilide with Phenol ........................ 64
3.10 C onclusion ...................................................................................... 71
3.11 Perspectives.................................................................................... 71
Chapter 4: Experim ental............................................................................. 73
4.1 Synthesis of Haptens and Substrates ............................................. 73
4.1.1 General M ethods ................................................................ 73
4.1.2 Synthesis of Hapten 72 ...................................................... 74
4.1.2 Synthesis of Hapten 74 ...................................................... 82
4.1.3 Synthesis of the Substrate 75 .......................................... 88
4.2 Biological M ethods ......................................................................... 89
4.2.1 Preparation of Carrier Protein-Hapten Conjugates ....... 89
4.2.1.1 Carrier Protein-72 and -74 Conjugates ............... 90
4.2.1.2 Carrier Protein-73 Conjugate .............................. 90
4.2.2 Im m unizations ................................................................... 90
4.2.3 Enzyme Linked ImmunoSorbent Assay (ELISA) ............ 91
4.2.4 Preperation of media ......................................................... 93
4.2.5 Preperation of Myeloma cells ........................................... 94
4.2.6 Determination of Cell Viability ....................................... 95
4.2.7 Fusion ................................................................................. 95
4.2.8 Limiting Dilution (Subcloning) ......................................... 97
4.2.9 Cryogenic Storage of Cell Lines ....................................... 98
4.2.10 Ascites Production From Monoclonal Hybridomas ........ 98
4.2.11 Purification of Monoclonal Antibodies ............................ 99
4.2.12 Assays for Catalysis.........................................................100
Biographical Note.........................................................................................102
References......................................................................................................103
Chapter 1
Introduction
Catalysis of biological, chemical and industrial processes is a thriving area of
research due to its scientific as well as economical importance. Thus, in 1989 more
than $1 trillion worth of goods was produced in the U.S. that made use of a catalytic
process. This is equivalent to roughly 30% of the U.S. Gross National Product for
that year1 . The demand for rationally-designed and highly selective catalysts is
greater than ever with a growing emphasis on the stereo-selective synthesis of
therapeutics. The late 1970's and early 1980's saw the development of organo-
metallic catalysts that accomplished some very important organic transformations
with high enantio- and diastereo-selectivities. In a monumental report in 1983,
Masamune and Sharpless reported the high-yield stereospecific synthesis of all of
the eight isomers of L-hexoses starting from an achiral building block and using a
simple reiterative two-carbon extension protocol coupled with a chiral catalyst 2. In
the following years to date, the field of asymmetric organic synthesis has been
expanding with continuous development of catalysts and ligands for a variety of
reactions ranging from Diels-Alder reaction to Michael Addition 3 .
With growing environmental concerns in the 1990's, there is an increasing
demand to use biological or bio-compatible catalysts. Enzymes offer themselves to
such use with their superb catalytic efficiencies, which in some cases reach the
ceiling that is dictated by the rate of diffusion in solution. On the other hand, the
high substrate specificity of enzymes have limited their use as applied catalysts,
and only in a few cases it has been possible to manipulate this specificity to derive
economic benefits; for example in the production of high-fructose corn syrup.
Another set of biomolecules that rival enzymes in their binding specificity are
antibodies. Using an elaborate mechanism of genetic recombination followed by
somatic mutation and affinity maturation, antibodies can be made in mammalian
systems that bind almost any given molecule with high specificity and affinity.
The harvesting of this tremendous potential toward catalysis was first hinted
at by Pauling4 who proposed fifty years ago that both enzymes and antibodies use
similar binding interactions, but enzymes selectively bind the transition state of a
reaction thus lowering its free energy of activation while antibodies bind ground
state structures. Thus, he concluded that catalysis is only accomplished by the
former species. In 1969, W.P. Jencks suggested that if an antibody were induced to
a transition state analog, it could serve as a catalyst for the corresponding reaction 5.
This proposal inspired a number of research groups to work on synthesizing
transition state analogs and generate antibodies. Before the eventual success in
1986, the most significant of these early studies is that of Raso and Stollar 6 between
1973 and 1975. They aimed to prepare polyclonal antibodies that could catalyze the
formation of Schiff base 3 by condensation of pyridoxal phosphate and tyrosine, and
hopefully, also catalyze the reactions that proceed via intermediate 3, such as
transamination. Polyclonal antibodies were prepared to two different haptens, 1
and 2 that were designed to mimic the Schiff base 3. (In subsequent work, these
haptens were shown to cause inhibition of tyrosine transaminase and tyrosine
decarboxylase). Although a five-fold rate acceleration of the transamination of
tyrosine to the corresponding c-keto carboxylic acid was observed with the
polyclonal antibodies to 1, neither the individual accelerated step of this reaction
nor the kinetic characteristics of the catalysis could be determined due to the
heterogeneous nature of the polyclonal antibodies. The authors drew a rather
pessimistic conclusion and abandoned any further investigation.
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The introduction of monoclonal antibody technology by Kohler and Milstein 7
in the following year rekindled interest in generating catalytic antibodies,
particularly that of Tramontano and Lerner 8. They were intrigued by earlier
studies that phosphate, phosphonate and phosphonamidate structures serve as
effective transition state based inhibitors of acyl transfer enzymes 9. In 1984, they
launched a program to synthesize the phosphonate hapten 6, in order to raise
antibodies that would catalyze the hydrolysis of the coumarin ester 4. Three of the
18 monoclonal antibodies they subsequently screened appeared to have esterase
activity, hydrolyzing coumarin ester 4. However, when one of these antibodies,
6D4, was studied in more detail, it was apparent that the reaction was
stoichiometric and not catalytico0 .
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Antibody 6D4 was subsequently examined with an alternative ester substrate
5 and catalysis was observed 11. The antibody was reported to obey classical
Michaelis-Menten kinetics (kcat = 1.62 min 1 ; Km = 1.9 gM), and bound the
transition state analog 6 with greater affinity (Ki = 0.16 gM) than the ester
substrate (5).
Simultaneously, Schultz12 reported a monoclonal antibody that catalyzed the
hydrolysis of carbonate 7. In his more efficient approach, he realized that one of the
numerous antibodies to phosphocholine esters (8) that had been previously raised
and characterized by others could act as a catalyst if the corresponding carbonate 7
was synthesized and screened. This approach indeed provided him with two
catalytic antibodies, MOPC167 and TEPC-15, that hydrolyzed the p-nitrophenyl
carbonate 7 with Michaelis-Menten kinetics. Antibody MOPC167 was then
characterized to have kcat = 0.4 min-1 ; Km = 208 •M; and Ki = 5.0 gM.
0O°rO-R HO,.op (
02N O'O I
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These two initial accounts were quickly followed by a number of other reports
where haptens were designed to mimic the transition state of reactions based on
simple charge and steric complementarity. Thus, phosphonate haptens were used
to induce the catalysis of acyl transfer reactions of various types13, and the six
membered transition state of a Claisen rearrangement 14 was mimicked by a stable
six-membered hapten. This initial design concept of charge and shape
complementarity can be thought of as a first generation of hapten design.
The second generation of hapten design was first reported by Schultz. 15 His
approach was to generate a basic residue in the antibody-binding sites via charge
complementarity to a positively-charged hapten. Such charge complementary salt-
bridge interactions between antibody-antigen pairs had previously been shown by
X-ray crystallography studies 16. Hence ammonium hapten 9 was synthesized and
was subsequently shown to effect the P-elimination of the 2-fluoroketone 10. (Janda
and Lerner also arrived at this concept, naming it "Bait and Switch" catalysis 17 and
applied it to ester hydrolysis - vide infra.)J OHF 0 HF0
0 2  HOH 02N02N 02 Z*ý.0 2NZý
9 10
The reader can easily imagine that a third generation hapten design would
comprise the combination of the two principles in the form of a zwitterionic
ammonium-phosphonate hapten. This concept was indeed investigated in 1990 in
the Masamune laboratories 18. The zwitterionic 1,2-amino-phoshinate hapten 11
was designed with the aim of generating ester and amide hydrolyzing antibodies
that incorporated a catalytic diad of acidic and basic residues in their active sites.
These residues were expected to aid in the hydrolysis of the substrates 12a and b in
a similar way to the mechanism of aspartic protease enzymes. However, during the
synthesis of hapten 11, we realized the synthetic challenge involved with such
zwitterionic structures, and decided to seek alternative approaches.
Based on our knowledge of the concept of "original antigenic sin" (explained
in detail in chapter 2) we imagined to separate the charged portions of hapten 11
into two structurally similar haptens 13 and 14, and immunize in succession with
both haptens. This process was termed "heterologous immunization" and indeed
provided more efficient esterolytic antibodies than the immunization with only one
of these haptens (homologous immunization) 49. Unfortunately, this protocol, by
itself, remained unsatisfactory for the ultimate goal of amide hydrolysis.O *ý C NH®+PdOR Ola0"0 o)oYx No o
000 0
N OH 0 N OHH H
11 12a X = NH
12b X = O
O oNý 0 OH
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The hydrolysis of amide bonds is an important target for antibody catalysis.
As these bonds constitute the backbone of proteins, selective and efficient cleavage
of amide bonds will undoubtedly create important therapeutic and industrial
applications for antibody catalysts. In light of the apparent failure of heterologous
immunization to generate amidase antibodies, we decided to supplement the
heterologous immunization protocol with the incorporation of an auxiliary
nucleophile into our hapten design. We envisioned using phenol as an auxiliary
nucleophile to effect the cleavage of the amide bond, similar to the use of co-factors
by enzymes. Additionally, heterologous immunization was employed to generate bi-
functional catalytic residues in the antibody binding sites. This approach has indeed
afforded amide hydrolyzing antibodies of superior catalytic efficiency.
A short review of previous efforts to generate catalytic antibodies with acyl-
transfer capabilities, including heterologous immunization, will be presented in
chapter 2. Subsequently, chapter 3 will disclose our fruitful attempt in the
generation of amidase antibodies via auxiliary nucleophile catalysis. Finally, the
experimental details of the work will be presented in chapter 4.
16
Chapter 2
Background: A Brief History of Catalytic Antibodies for Acyl
Transfer Reactions
In this chapter, the progressive sophistication of hapten designs for acyl
transfer reactions will be reviewed. The ultimate goal of these efforts has been to
establish a reliable method to cleave amide bonds by antibodies. The progress made
will be presented in four steps: 1) pentavalent phosphorus haptens based on steric
complementarity; 2) haptens that emphasize charge complementarity; 3) bi-
functional haptens presented in a heterologous immunization protocol; 4)
combination of heterologous immunization with nucleophilic catalysis.
Significantly, the last two approaches have been conceived in the Masamune
laboratories and involved the efforts of the author. The successful outcome of the
final design which has finally afforded effective amidase antibodies will be described
in Chapter 3.
2.1 Phosphate, Phosphonate and Phosphinate based Haptens
After the initial reports by the Lerner and Schultz groups, a wealth of
research on antibody catalysis followed to exploit the suitability of the oxy-anionic
phosphorus center to mimic the tetrahedral transition state of acyl transfer
reactions. The suitability of phosphorus haptens stems from a number of factors: 1)
the tetrahedral orientation of ligands around the pentavalent phosphorus center; 2)
the partial negative charge that is present on the phosphorus oxygens; 3) the
effective mimicking of the scissile C-O bond by P-O bonds that are 15% longer than
a ground state C-O bond.
Many of the early reports have concerned the catalysis of ester and carbonate
hydrolysis/formation reactions because of their relatively low energy of activation.
17
While the importance of catalyzing the hydrolysis of amide bonds has also been
realized early on, reported attempts toward this end have been few. This probably
also reflects the fact that many failed attempts were not reported.
The early studies established that antibodies raised to pentavalent
phosphorus haptens could bring about ester and carbonate hydrolysis with rate
accelerations typically 103 over the uncatalyzed reactions. As comprehensive
reviews of these early efforts already exist in the literature 19, this section will
discuss only those examples where ester or carbonate hydrolysis by an antibody has
been coupled to other important criteria such as regio- or enantio- selectivity,
degradation of a narcotic, or the activation of a pro-drug. These should also illustrate
some of the inherent power of using antibodies as catalysts. While apparently
sufficient in ester and carbonate hydrolysis; the simple phosphonate hapten design
has been generally unsuccessful in generating amide hydrolyzing antibodies.
However, a handful of exceptional cases will be discussed at the end of this section.
2.1.1 Regioselective Ester Hydrolysis by Catalytic Antibodies
Antibodies have unique three dimensional binding sites that can be
programmed by the appropriate hapten to achieve site-selective catalysis of a
substrate. This obviates the need for the protection or chemical differentiation of
similarly reactive sites in the molecule.
Fujii and co-workers raised antibodies to the phosphonate hapten 18 to
selectively hydrolyze the 4'-phenylacetate moiety of the 3',4' protected carbohydrate
1920 . The phosphonate of the hapten was positioned to correspond to the 4'-
phenylacetate of the substrate. Furthermore, by using a rather large sized hapten
it was hoped that the antibodies would tolerate substrate variability at the 1' and 2'
positions of the carbohydrate, thus generating catalysts with wide substrate
applicability.
-oNH0 ) nOH
R
AcNHAcNH
OMe
19a: RI=AcNH-Phe-CH 2-C0 2 R2 =H R3 =AcNH
18 19b: R 1=H R2=AcNH-Phe-CH 2-CO2 R3 =AcNH
19c: RI=AcNH-Phe-CH 2 -CO2 R2=H
R3 =AcNH-Phe-CH 2-CO 2
12 monoclonals were generated to 18, two of which were found to selectively
hydrolyze at the 4' position of the substrate 19a. One of these, 17E11 was
characterized in further detail. It displayed a kcat = 0.182 min-1 which
corresponded to 2740 fold rate acceleration, and was competitively inhibited by
hapten 18. Almost perfect regio-selectivity was observed when a large amount of
the antibody catalyst was used. Furthermore, this antibody was shown to be stereo-
selective, the 4'-axial enantiomer, 19b was not accepted as a substrate. Finally,
using the tri-ester substrate 19c the authors showed that the antibody could
selectively enhance the hydrolysis of 4'-ester 91 fold over the other two positions of
the carbohydrate. This study is especially important given the ubiquitous presence
of carbohydrates in antitumor and antibacterial agents.
2.1.2. Enantioselective Ester Hydrolysis by Catalytic Antibodies
The tight binding specificity of antibodies to their substrates dictates that
only one enantiomer is selectively bound and accepted as a substrate. This implies
that the use of an enantiomerically-pure hapten will generate antibodies that
should only catalyze the corresponding enantiomeric transition state. On the other
hand, if the requirement is the enantioselective catalysis of the either enantiomer
without specification, then catalytic antibodies offer even a bigger advantage. A
racemic hapten can be used as each monoclonal antibody will be raised to only one
I
enantiomer of this racemate and thus accept only the corresponding substrate.
Hence, a racemic hapten will often generate a pool of catalytic antibodies each of
which will specifically produce a single stereo-isomer of the product. In theory this
concept can be extended to an infinite number of stereomeric centers. The limit is
imposed only by the maximum number of catalysts that can be isolated with the
present hybridoma technology (usually around 100) so that each stereo-isomer-
specificity can be statistically represented in the final antibody pool.
Demonstration of the above principle was first achieved by Napper and co-
workers 21 when monoclonal antibodies were raised to the racemic hapten 20. One
of these antibodies, designated 24B11, selectively catalyzed the enantiospecific
cyclization of ester 21 to give lactone 22 with a 66% observed enantiomeric excess
(ee). The low enantiomeric excess is not due to poor selectivity, but rather to the
small ratio of kcat /kuncat (167, kcat = 0.5 min- 1). This translates to an e.e. of 94%
for the antibody-catalyzed reaction. Significantly, the observed catalysis ceases at
50% consumption of the racemic starting material, a result expected for an enantio-
specific catalyst.
PhO. 00
H 0 OH 24B11
N %OH Ph. NHAc NHAc
0 0
20 21 22
Subsequently, it was shown that the same antibody could also catalyze the
stereospecific aminolysis of 22 with 1,4-phenylenediamine with higher than 90%
e.e. 22 Although 16 M effective molarity increase was observed for 1,4-
phenylenediamine, the reaction was effectively inhibited by the amide product (Ki =
35 gM). The authors claimed independent binding sites for both 22 and 1,4-
phenylenediamine; however, some important control experiments were neglected,
such as antibody specificity for 1,4-phenylenediamine.
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Application of enantioselective antibody catalysis to natural product
synthesis was first demonstrated by Janda, Danishefsky and coworkers 23. Thirty-
three monoclonal antibodies were raised to the phosphonate hapten 15. One of
these, antibody 37E8 hydrolyzed meso-16 with kcat = 0.007 min-1, Km = 177 RM, and
Ki = 7.0 pM to afford (1R, 4S)-17 with 86% ee. Product 17is a starting material in
the stereoselective total synthesis of prostaglandin F2a. Although the 86%
enantioselectivity of 37E8 appears modest, the limitation is imposed by the poor
rate acceleration achieved by the antibody as the competing background reaction
proceeds stereo-randomly. The authors determined that the inherent
stereoselectivity of 37E8 was very high (>98% ee).
HO OO O O oO <HO* yO
15 16 (1R,4S)-17 (86% ee)
Using racemic hapten 23, Janda et al. was able to isolate nine monoclonal
antibodies that catalyzed the hydrolysis of (R)-24, and the other two of the (S)-2424.
One from each group, 2H6 and 21H3, specific for the (R)- and (S)- substrates,
respectively, were characterized further. Antibody 2H6 was found to be particularly
effective at accelerating the reaction, with kcat/kuncat = 80,000, but the product acid
was a strong competitive inhibitor of the hydrolysis with Ki = 50 gM. This result, in
part, prompted these workers to immobilize both catalysts, 2H6 and 21H3, on solid
inorganic supports so that ultimately product could be removed in a continuous flow
reactor system 25. The kinetic parameters of the immobilized antibodies compared
well with the free antibody, and for 2H6 these values were stable for over three
months. Immobilized antibody 21H3 also retained 40% activity in a 40% DMSO
assay solution, whereas free antibodies lost activity after a one-hour exposure.
0" 0 0T0 0
O6N OH O0N 0ONH H
23 (R)- or (S)-24
000 0
OHN OH
H
(R)- or (S)-25 26
Subsequently, it was shown that antibody 21H3 could also catalyze the
reverse reaction, namely the trans-esterification of vinyl ester 26 with (S)-25 to give
(S)-2426. A ping-pong mechanism with a covalent intermediate was proposed. 21H3
was able to accept a variety of aromatic alcohols similar to 25, and therefore it was
claimed that these alcohols bound antibody with an induced fit mechanism - an
unequivocal proof of which is only possible by determining x-ray crystal structures.
2.1.3 Cocaine Degradation by Catalytic Antibodies
Cocaine addiction is a serious current problem that afflicts most western
cultures. There are no known antagonists of cocaine receptor, and it has been
shown that antibodies that simply bind the receptors of narcotics such as heroin,
are easily overwhelmed by repetitive high doses. Cocaine (28) involves two ester
moieties that are perfectly poised for antibody catalysis. Upon cleavage of the
benzoate, the non-neuroreactive ecgonine methyl ester 29 is produced. The
research group of D. W. Landry raised antibodies to the hapten 27 which was
designed to mimic the transition state for the hydrolysis of the benzoate of cocaine
(28)27. Two out of the 29 antibodies tested catalyzed this hydrolysis reaction, and
3B9 was shown to offer 540 fold rate enhancement compared to the background
22
reaction. The authors concluded by citing that roughly 1000 fold more efficient
catalysts would be needed for use in animal clinical studies.
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2.1.4. Pro-drug Activation by Catalytic Antibodies
The use of pro-drugs is an interesting approach for the site-specific delivery of
drugs to avoid unwanted side effects. This approach often relies on the presence of
an enzyme or some other conditions that is specific for the pro-drug and localized to
the target area so that the liberation of the drug occurs solely at this locale. With
their programmable specificities, antibodies have a tremendous potential in this
area with the choice of a reaction that has a negligible background reaction by non-
specific endogenous enzymes. Furthermore, chimeric bi-functional antibody
technology offers to take this utility one step further by generating antibodies that
recognize a target (e.g. tumor) cell with one binding site and catalyze the activation
of the pro-drug with the other binding site28.
The first group to realize the pro-drug activation potential of catalytic antibodies
has been that of Fujii where they raised antibodies to the phosphonate 33 to cleave
a phenyl acetate 30 and liberate the antibiotic chloramphenicol 3229. As the phenyl
acetate exists as a mixture of two isomers 30 and 31, antibodies were also raised to
the C-1 analog hapten 33. None of the 23 antibodies raised to this hapten were
found to be catalytic, while 6 out of the 12 to hapten 34 were. One antibody, 6D9
was characterized further and was found to accelerate the hydrolysis of 2 2000 fold
over the background rate. It displayed multiple turnovers, as well as growth
23
inhibition in a bacterial assay. In a paper-disc agar diffusion assay, the
combination of the pro-drug and antibody 6D9 inhibited the growth of bacteria in a
circular zone of 12 mm. The authors commented that this protocol could be used as
a selection tool during the phagemid expression of antibodies in bacteria.
p ,..NHCOCF3 0 ,0:" NHCOCF 3
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Another pro-drug activation study came from the laboratories of Peter
Schultz, where antibodies were raised to catalyze the hydrolysis of the 5'-D-Val
ester 35 of the antitumor agent 5-FdU 363o. They used a phosphonate analog
hapten 37 and achieved a rate acceleration of 103 with antibody 49.AG.659.12. The
non-natural D-isomer of valine was used as most endogenous esterases can not
hydrolyze D-amino acid esters.
Ac0 O Ac OU IAC,+ ,,
NH QH NH NH
NO HO0 NO(0NO0C-O C O NPO
-Oo O ý
49.AG.659.12
HO HO HO
5-FdU 36 37
A
The activity of 49.AG.659.12 was tested in vitro where it inhibited the growth
of E. Coli in the presence of the prodrug, while the prodrug alone showed no growth
inhibition.
2.1.5. Investigations of Amide Hydrolysis by Catalytic Antibodies Raised to
Phosphonate Haptens
Ironically, the most encouraging report of antibody catalyzed amide
hydrolysis was the first one. Janda et al. raised 44 monoclonal antibodies to the
phosphonamide hapten 38, one of which was found to accelerate the hydrolysis of
the p-nitroanilide substrate 3931. Antibody NPN43C9 displayed Michaelis-Menten
kinetics (kcat = 0.05 min-1, Km = 562 gM ) and was competitively inhibited by
hapten 38 (Ki = 10 gM). Unfortunately, this catalyst also displayed strong
inhibition by the products of the reaction as well as high salt concentration. Thus, it
is likely that this antibody did not achieve many turnovers. The catalytic activity
was shown to be very substrate-specific, m-nitroanilide or other para-substituted
anilides were not accepted as substrates. Interestingly m-nitroanilide was a
competitive inhibitor of the reaction. This suggests that a specific binding pocket
for the aromatic nitro group had been formed and that the lack of catalysis is
probably due to the incorrect orientation of this substrate in the binding pocket.
This is in accord with the known strong immunogenicity of aromatic nitro
compounds.
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Since this initial report, a number of mechanistic studies of antibody
NPN43C9 has shown that catalysis takes place by the formation of an acylimidazole
intermediate with a histidine residue in the antibody binding pocket. Details of this
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seemingly fortuitous mechanism, as well as its implications on the importance of
nucleophilic catalysis to antibody catalyzed amide hydrolysis will be discussed in
section 2.4.
Subsequently, Janda et al. tried to improve on this catalyst by using a
combinatorial library approach to raise antibodies to phosphonamidate 3832. This
technique isolates the genes that code for different antibodies directly from the
immunized animal and expresses different antibody binding sites by cloning the
genes into bacterial hosts. Of all of the different 38-binding antibodies that were
screened, none catalyzed the hydrolysis of 39 although one, 1D, did catalyze the
hydrolysis of the corresponding ester with modest rate acceleration. This result
underscores the difficulty and improbability of generating an amide-hydrolyzing
antibody by simple phosphonate haptens.
An interesting approach to cleaving peptide bonds has been reported by
Benkovic where the target reaction was the well-documented B-aspartyl shift, a
natural mechanism of the aging of proteins 33. This report described antibodies
raised to the bi-functional hapten 40 , which catalyzed the conversion of asparginyl-
glycyl(N-phenethyl)amide 41 first to succinimide 42, and subsequently to the
hydrolysis products 43 and 44.
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These conversions can potentially provide an alternative means (to direct
amide bond cleavage) for the deactivation of protein functions in vivo. Hapten 40
was designed so that its two tetrahedral transition state analogs (phosphonate and
secondary alcohol) could mimic all of the transition states on the pathways leading
from substrate 41 to the B-aspartyl shift product 43, or, to the aspartate
deamination product 44. In the initial report, two monoclonal antibodies (2E4 and
24C3) were found to accelerate the cyclization of 41 to 42 and 2E4 was characterized
kinetically to have kcat = 0.0072 min -1 at pH 9.0 which corresponds to a rate
acceleration of only about 70 when compared to the water catalyzed reaction.
A later comprehensive analysis found that two classes of catalytic antibodies
had been generated 34: those that only catalyze the hydrolysis of the succinimide 42,
and those that catalyze both the cyclization of 41 to succinimide 42, as well as the
subsequent hydrolysis of 42. Antibody 23C7 from the first group and 23E4 from the
second group were characterized for their substrate specificities and product ratios.
Whereas the uncatalyzed reaction gave products 43 and 44 in a ratio of 3.7:1,
antibody 2E4 produced these products in a lower ratio (~-1) when the substrate was
the L-isomer, and in a higher ratio (7:1) when the substrate was the D-isomer. This
selectivity was reversed with antibody 23C7 giving 1:1 ratio of the products with the
D- isomer and 1:30 with the L- isomer. As a racemic hapten was used, the authors
rationalized these results by proposing: 1) 23C7 had been generated by the D-isomer
of the hapten while 2E4 had been raised to the L- hapten; 2) the antibody binding
site complementary to the phosphinate moiety of the hapten is four-fold more
reactive than the site raised to the secondary alcohol; and 3) both isomers of the
substrate can be bound as the N-acetyl group of the succinimide 42 corresponding to
the linker group of the hapten does not make significant binding interactions with
these antibodies.
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Again targeting a primary amide, M. T. Martin et al. raised 68 monoclonal
antibodies to the phosphonate 45 and found that one of these accelerated the
hydrolysis of the dansylated phenylalanine primary amide 46 132 times over the
background reaction 35. An interesting aspect of this work is the early screening
method that was utilized. Antibodies from the cell supernatants of the 68
monoclonals that initially bound to the hapten were immobilized on a gel matrix.
These were directly screened for catalysis in the presence of 4 primary amide
substrates (46a,b ; 47a,b) and 4 methyl ester substrates (46c,d; 47c,d) at three
different pH values. After each reaction, the antibody in the solid phase was
recycled by simple filtration. The immobilized antibodies were shown to be stable
after 24 such reaction cycles. Furthermore, incorporation of a dansyl chromophore
in the linker portion of the substrates enabled these workers to perform a rough fast
screen for catalysis via thin layer chromatography. The most efficient catalyst
13D11 was shown to be specific for the (R)-46b and did not catalyze the hydrolysis
of the corresponding methyl ester 46d.
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Maximum activity was observed at pH 9.5 and was completely inhibited upon
the addition of one equivalent of hapten. Surprisingly, this antibody required the
presence of the dansyl group in the substrate although this group was absent in the
inducing hapten. Thus, acetyl substrate 47b was not accepted for catalysis.
The above three studies show that although amide hydrolyzing antibodies
have been obtained with simple phosphorus based haptens, the catalytic efficiency,
as well as the probability of finding a catalyst have been quite poor. This is
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probably due to the fact that these haptens only emphasize the formation of an acid
residue in the antibody binding sites that facilitates the transition state for the
formation of the tetrahedral intermediate. On the other hand, mechanistic studies
of amide hydrolysis have shown that the rate determining transition state is that of
the breakdown of the tetrahedral intermediate with the departure of the amino
group 5. As it is known that the relatively facile amidase antibody NPN43C9 acts by
a fortuitously-induced nucleophilic catalyst, it can be speculated that the latter two
inefficient amidase antibodies may be acting by a mechanism where the induced
acidic residue is in the proximity to shuttle its proton to the departing amine, albeit
inefficiently. What is needed then, is a paradigm to generate a more effective
proton donor to the departing amine, in addition to the stabilization of the
tetrahedral intermediate.
2.2 Second Generation Haptens Based on Antigen-Antibody Charge
Complementarity or Metal co-factors
After the seminal report of Schultz that a charged ammonium hapten (9)
could generate antibodies that catalyzed a P-elimination reaction 15, ostensibly
through the generation of a charge-complementary basic antibody residue, two
research groups independently envisioned that a similar basic residue could be
utilized in ester and amide hydrolysis. This basic residue would be used to
deprotonate an incoming water molecule, and also shuttle the removed proton to the
departing amine or alcohol to increase its leaving group ability.
The research group of Janda was the first to report the application of this
design to ester hydrolysis, with the use of a pyridinium secondary alcohol (vide
infra)36. Although this design was successful in generating esterolytic antibodies, it
carries an inherent limitation. The ester substrate must be a benzoate due to the
incorporation of the positive charge into an adjacent aromatic ring. On the other
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hand, our own design which was subsequently-reported is free of this limitation and
is more generally applicable due to the employment of an alkyl ammonium alcohol
for the same purpose (vide infra)39.
Finally, Iverson et al. used a metal trien complex to generate antibodies that
would hydrolyze amide bonds via the activation of the amide bond with metal
coordination (vide infra)41. Although seemingly successful, the discrepancy between
the accepted substrate and the inducing metal-trien hapten hints at the fortuitous
nature of this finding; especially after a similar, if not more sophisticated approach,
was found to be unsuccessful by Blackburn et al.42
2.2.1 Pyridinium Alcohol Haptens for the Antibody Catalyzed Hydrolysis of
Benzoate Esters
Janda et al. raised antibodies to the pyridine-derived haptens N-methyl
pyridinium 48 and uncharged 4936 . Approximately twenty antibodies raised to
each hapten were screened against benzoate 50. None of the antibodies raised to
hapten 49 were able to catalyze the hydrolysis of ester 50, while seven of the
antibodies raised to the N-methyl-pyridinium hapten 48 were found to be catalytic.
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These antibody catalyzed reactions could all be inhibited in a competitive
manner with their corresponding haptens. Antibody 30C6, displayed Michaelis-
Menten kinetics where: kcat/kuncat - 100; Km = 1.12 mM; and Ki = 83 gM. The pH-
rate studies pointed to the involvement of a basic residue in the antibody binding
site with an apparent pKa of 6.3 thus confirming the success of the charge-
complementarity approach to the generation of esterolytic antibodies.
Subsequently, Janda et al. prepared three more haptens 51, 52 and 53 to
determine the importance of charge and the ability of a secondary alcohol to
function as an effective mimic of the acyl transfer transition state37. After
screening twenty-two antibodies specific for hapten 53, no significant catalysis was
observed in the hydrolysis of benzoate 50. Substituting the secondary alcohol for a
quaternary ammonium group (hapten 52) also failed to provide catalytic antibodies.
On the other hand, three out of eighteen antibodies raised to hapten 51 catalyzed
the hydrolysis of benzoate 50 and could be competitively inhibited. One antibody
27A6 was characterized further and showed increasing catalytic activity as the pH
of the reaction medium was increased, but no ionizable antibody residues. This
suggests that this antibody relied on general base catalysis from the solvent for its
catalytic activity. These results prompted the authors to conclude that a
combination of both charge and transition state complementarity is critical in
obtaining antibody acyl transfer catalysts.
2.2.2 Esterolytic Antibodies Induced to Haptens with a 1,2-Amino Alcohol
Functionality38
We have designed and synthesized three haptens 54, 55, 56 based on an
amino alcohol framework to test the correlation between hapten structure and
catalytic efficiency 39. Another goal of the study was to establish how the binding
affinity to haptens, substrates or products relates to the observation of catalysis.
All three haptens incorporated a positively charged ammonium moiety next to a
secondary alcohol and the size difference between the hapten and the substrate was
varied. Hapten 54 contained a primary ammonium next to a secondary alcohol
while hapten 55 reproduced the same structure but with a quaternary ammonium.
When the hapten is replaced with the substrate, the position of this amine was
expected to provide a convenient binding site for the water nucleophile. Finally,
hapten 56 carried an additional negatively charged phosphate to induce an acidic
residue that would stabilize the oxy-anion transition state, albeit with some
structural mismatch. Thirty-four, 48 and 20 monoclonal antibodies were generated
to these haptens, respectively, and each antibody was tested for catalyzing the
hydrolysis of the p -nitrophenyl ester 57a.
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Interestingly, all of the three haptens were able to generate esterolytic
antibodies with roughly similar rate accelerations (kcat/kuncat = 1-3 x 103). In a
study first of its kind, the dissociation constants (Kd's) were measured to substrates,
respective haptens and products. No major differences in binding affinities were
observed between catalytic and non-catalytic antibodies from each of the three
haptens. This confirmed our belief that antibody catalysis relies on the generation
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of appropriately placed catalytic residues in antibody binding sites and not on a
general paradigm of binding affinity.
Another significant finding of the study was that hapten 54 gave the highest
probability of generating catalytic activity with 16 out of the 34 antibodies induced
to this hapten being catalytic. Whereas 7 out of 48, and 4 out of 20 haptens were
found to be catalytic with haptens 55 and 56, respectively. It was deduced that the
quaternary ammonium of the latter haptens were ineffective presenters of the
haptenic positive charge to the antibody repertoire probably due to the steric
interference of the methyl groups. Additionally, the phosphate group of hapten 56
was deemed too large to generate a useful acidic residue in proximity to the reaction
site. None of the antibodies generated to the three haptens were seen to accelerate
the hydrolysis of the amide substrate 57b 40.
The most important conclusion that can be derived from the above two
studies is that hapten-designs based on charge-complementarity could generate
esterolytic antibodies with similar catalytic efficiencies (kcat /kuncat = 1000) to
antibodies generated to phosphonate haptens, while this new design principle still
proved inadequate to provide amidase antibodies. We proposed that the use of
zwitterionic haptens were essential for the generation of the amidase catalysts.
Unfortunately, the synthesis of such zwitterionic haptens presents considerable
synthetic challenge. This problem was circumvented by our development of a
unique immunization protocol, named heterologous immunization 49 which will be
described in section 2.3.
2.2.3 Metal Based Haptens to Generate Amidase Antibodies
Metal ions are known to catalyze the cleavage of amide bonds and certain
metallopeptidases, such as carboxypeptidase, use divalent metal cations as cofactors
in catalysis. Two mechanisms are available by which metal ions can facilitate
33
amide bond hydrolysis. Either the metal ion can polarize the carbonyl group by
coordination with the carbonyl oxygen, a process which assists nucleophilic attack
at the carbonyl carbon, or alternatively, the metal ion can directly deliver bound
hydroxide to the carbonyl carbon. By synthesizing a stable Co(III)trien complexed
to a tetrapeptide 58, Iverson and Lerner hoped to induce an antibody binding site
that would place the scissile bond of the substrate in close proximity to a bound
metal trien complex so that the amide bond hydrolysis could be catalyzed by one of
the two mechanisms described above41.
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Thirteen monoclonal antibodies specific for the hapten 58 were screened for
hydrolytic activity against six peptide substrates with several different trien metal
complexes. One antibody, 28F11, catalyzed the hydrolysis of substrate 59 in the
presence of trien ligand and several different metals including Zn(II), Fe(III),
Ga(III), Cu(II) and Ni(II). The most efficient metal cofactor complex compatible
with antibody 28F11 was reported to be a Zn(II)trien with optimum activity
between pH 6.0 and 8.0, although detailed kinetic studies were not undertaken.
Several issues call for a certain amount of skepticism when reviewing these results:
1) substrate cleavage occurred specifically at the Gly-Phe bond, a position somewhat
displaced from the anticipated metal binding site, 2) rate of background hydrolysis
in the presence of metal-trien complexes were not determined, 3) inhibition constant
with the inducing hapten was not reported.
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No doubt inspired by the above results of Iverson and Lerner, Blackburn
sought to improve on this design by incorporating a phosphinate moiety at the
haptenic site corresponding to the scissile amide bond, ensuring a more correct
orientation of the metal ligand 42. Initially, hapten 60 was synthesized involving the
original trien ligand. However, this compound was found to be poorly immunogenic
and the design was modified to the tris-pyridyl hapten 61. Unfortunately, no
further reports appeared on the immunization or catalysts generated with hapten
61. Thus, it is compelling to assume that the outcome of the immunological or
kinetic studies has been negative. Nonetheless, that of Blackburn represents one of
the most elaborate hapten designs that has been reported to generate acyl
hydrolyzing antibodies.
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2.3 Third Generation Hapten Design: Heterologous Immunization
As mentioned above, one of the conclusions of our studies with 1,2-amino
alcohol haptens was that zwitterionic haptens are probably essential to generate
amidase antibodies. We were inspired by the earlier immunological studies of
antibody cross reactivity to two distinct but structurally similar antigens that was
termed "original antigenic sin". We envisioned that the phosphinate and
ammonium groups of a zwitterionic hapten could be bisected into two haptens.
These could then be used to immunize in succession and generate antibodies that
would be cross reactive to both of the haptens, and display enhanced catalytic
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efficiency. This section will first present a brief outline of the studies on original
antigenic sin, and then discuss the successful outcome of the devised immunization
regimen that we termed "heterologous immunization"
2.3.1 Original Antigenic Sin
The humoral arm of the Immune system consists of up to 1010 different B-
cells each of which has a unique genetic formula to produce a unique antibody43.
Upon encounter with an antigen, the B-cells that produce antigen-binding
antibodies are proliferated. In the primary immune response, IgM class of
antibodies are produced which have low affinity to the antigen. If the antigen
presence persists, starting with the second week, the class of antibodies produced is
changed from IgM to IgG (the so-called "class-switch") which have longer lifetimes
in the blood-serum. Concurrently, the induced B-cells undergo a process called
"somatic mutation" where their antibody-specific genes are subjected to mutation
followed by continuous selection to give tighter-binding antibodies. After the
antigen threat is overcome, most of these B-cells are cleared from the body, but a
small subset is retained to serve as memory B-cells. When the same antigen is
encountered a second time, a secondary immune response occurs where the specific
memory B-cells are directly induced to proliferate, producing tight binding IgG class
antibodies.
In 1953, during the studies of immune response to different strains of
influenza virus, a phenomenon was observed which was later termed "original
antigenic sin"44. When animals that were already immune to a primary antigen
(viral coat protein) were stimulated with a different but related antigen it was seen
that the resulting polyclonal antibodies reacted stronger with the original antigen
than the secondary antigen. A number of studies ensued to investigate the issue
but these were more speculative in nature than conclusive 45.
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Finally, Bussard et al. studied this phenomenon in more quantitative
terms46. Two structurally similar haptens, m-aminobenzoic acid 62 and m-
sulfanilic acid 63 were used as haptens and the number of specific B-cells generated
were used to quantitate the strength of each immune response. The use of
molecularly defined haptens assured the uniformity of the immunization
procedures. In animals immunized with only one of the haptens, no cross-reactivity
to the other hapten was observed. In contrast, when animals were immunized with
62 followed by 63 they displayed a similar-strength response to both haptens, and
with the reverse regimen, a stronger response to the primary (63) hapten. Clearly
in both cases, the secondary antigen was triggering the production of antibodies
from memory B-cells that had already been generated toward the primary hapten.
00 0
OH-t- 
N-N-- SOOO 
H OH NO
H2 N H2 N62 63 64 65
This hypothesis was subsequently proven at the molecular level by Manser et
al.47 after the development of hybridoma and DNA manipulation technologies in the
early 80's. From their earlier studies, these researchers had already determined the
genetic make up of the immune response to a p-azidophenylarsonate (64) hapten48.
By immunizing animals already immune to 64 with a structurally similar p-
azophenylsulfonate (65) hapten and determining the genetic make up of antibody
response, they could show that the same gene family was used to bind both the
primary (64) and the secondary (65) haptens. Furthermore, they could show that
the development of the cross-reactivity was achieved by the 65-induced somatic
mutation of variable region genes in 64-specific memory B-cells.
As encouraging as these landmark studies were, it should be noted that the
structural variation between the primary and secondary antigens was quite small.
Thus, it was not clear whether the same "original antigenic sin" mechanism could
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be recruited to cross-reactively respond to two haptens that would incorporate two
opposing point charges in their nonetheless-similar structures. Fortunately, this
was a risk we were willing to take.
2.3.2 Esterolytic Antibodies Generated by Heterologous Immunization
With the aim of generating amidase antibodies that catalyze the hydrolysis of
amide 57b, we raised antibodies to haptens 55 and 38 using the heterologous
immunization protocol 49. Thus, mice were immunized twice with 55 and a final
boost was delivered with the phosphonamidate hapten 38 before the production of
hybridomas. As a control, antibodies were also raised to hapten 55 and 38 alone
(homologous immunization). It was found that 19 out of the 50 antibodies
generated by the heterologous immunization catalyzed the hydrolysis of ester
substrate 57a, while only 7 of the 48 antibodies raised to 55 alone displayed
catalysis. Furthermore, 9 of the 19 heterologous catalytic antibodies displayed
grater than 104 acceleration, while the seven homologous catalytic antibodies to
hapten 55 all had similar rate accelerations of about 103.
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Homologous immunization with 38 also generated catalytic antibodies with
high probability (17 out of 48), however 12 of the 17 catalysts displayed strong
product inhibition with p-nitrophenol. The most efficient catalyst from this group,
antibody H2-23, displayed a rate acceleration of 11,000 and burst kinetics. However,
this initial burst was due to strong product inhibition by p-nitrophenol which
diminished catalytic activity by 30% after 5-6 turnovers.
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The best catalyst obtained from heterologous immunization, H5H2-42,
accelerated the ester hydrolysis 105 fold over the background reaction at pH 6.6 and
displayed more than 500 turnovers. It was shown to be competitively inhibited by
both 55 and 38, while no product inhibition was seen with either p-nitrophenol or
the acid. The pH dependence studies pointed to the existence of two ionizable
antibody residues that participated in catalysis with apparent pKa's of 5.6 and 8.7;
thus confirming the generation of bi-functional antibody residues with the
heterologous immunization strategy.
Interestingly, the reverse order of heterologous immunization, namely two
injections with 38 followed by a boost with 55 failed to give cross reactive
antibodies. Antibodies generated in this fashion were shown to have a weak affinity
to 55 and no affinity to 38. These were also shown to belong to the IgM subclass. All
of this evidence pointed to the fact that this immunization order simply led to a
primary immune response to hapten 55 rather than recruiting the memory B-cells
that were previously generated to 38. This was tentatively explained to be a
phenomenon of sterics where the bigger hapten 55 fails to bind and stimulate
epitopes that were originally generated to 38. However, it should be pointed out
that a similar phenomenon has also been observed with our subsequent studies in
heterologous immunization (see Ch. 3), and in that case sterics failed to offer an
explanation.
Dissociation constants (Kd's) of all (catalytic, non-catalytic, homologous and
heterologous) antibodies were measured to the amide substrate 57b, both of the
haptens and both of the products. No general differences were observed in the
binding affinity to the substrate showing that this is not a criteria for catalytic
efficiency. Catalysis by all of the homologous antibodies were specifically inhibited
by their inducing haptens but not with the opposite hapten. This pattern was also
reflected in the binding affinity (Ki's) of the homologous antibodies where minimal
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binding to the opposite hapten was observed. Finally, all of the catalytic antibodies
were assayed for catalyzing the hydrolysis of amide 57b and none of them displayed
catalysis.
As a summary, this seminal work on heterologous immunization has shown
that zwitterionic haptens can be dissected into two structurally-similar haptens and
used to generate antibodies that bind both haptens. Furthermore, it was shown
that heterologous antibodies are up to two orders of magnitude more efficient
catalysts than their homologous counterparts. On the other hand, this rate
improvement was not sufficient to achieve the catalysis of the corresponding amide
57b. A thorough re-evaluation of the mechanistic studies of serine proteases and
previous acyl-transfer antibodies pointed to nucleophilic catalysis as an effective
way to augment the rate accelerations achieved by heterologous immunization.
2.4 Fourth Generation of Haptens: Combination of Heterologous
Immunization with Nucleophilic Catalysis
The rate determining step of most amide hydrolysis reactions is the
breakdown of the tetrahedral intermediate to expel the amine5. Heterologous
immunization with oppositely charged haptens tries to facilitate this process by
generating residues to donate a proton to the departing amine. To find an extra
source of catalysis, we reasoned that the use of a more effective nucleophile than
water should lead to an increase in the population of the tetrahedral intermediate.
This could in turn lead to an increase in the rate of break-down of the tetrahedral
intermediate to an acid and amine. Similar nucleophilic catalysis is commonly
employed by enzymes, and it is significant that three out of the four classes of
proteases and all of the acyl hydrolyzing antibodies characterized so far display the
use of a fixed internal nucleophile.
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2.4.1 A Brief Synopsis of Proteolytic Enzymes
Proteolytic enzymes are commonly divided into four classes according to their
mechanism of action. With the exception of aspartic proteases, all of the other three
classes of proteases function by positioning the initial nucleophile that attacks the
amide bond at an optimal location. Hence, in the case of metalloproteases this
nucleophile is a hydroxide bound to a metal in the active site, and in serine and
cysteine proteases it is an active site alcohol or thiol residue, respectively50.
Of all the types of proteases, the mechanism of serine proteases has been the
most extensively studied. It involves a so-called "catalytic triad' of three active site
residues (scheme 2.1). The nucleophilic attack by an active site serine residue is
aided by general base catalysis by a histidine which is in turn activated by an
aspartate, leading to the formation of the acyl-enzyme tetrahedral intermediate.
The subsequent expulsion of the amine is aided by its protonation by histidine
generating the acyl-enzyme species. Then the process is repeated in reverse for the
hydrolysis of the acyl intermediate liberating the acid portion of the substrate.
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In addition to the catalytic triad, another feature of serine proteases that is
essential for catalytic activity is the so-called oxy-anion hole. This is formed by two
active site hydrogen-donor residues that stabilize the oxy-anionic tetrahedral
intermediates in the acylation and hydrolysis steps of the reaction.
As the phosphonate haptens are expected to generate the antibody equivalent
of this oxy-anion hole, and the complementary ammonium-alcohol haptens should
generate the equivalent of the general-base histidine residue (probably in the form
of a carboxylate); it became apparent to us that the remaining factor to simulate the
mechanism of serine-proteases was to incorporate a nucleophilic residue into our
antibody binding sites. This nucleophile should ideally be nucleophilic enough to
attack an amide bond, and also its formed ester should be facilely hydrolyzed in
water. Further support on the importance of nucleophilic catalysis to acyl
hydrolyzing antibodies was drawn from the mechanistic and structural studies of
esterase and amidase antibodies where researchers proposed similar acyl-antibody
intermediates.
2.4.2 Mechanistic and Structural Studies of Acyl Hydrolyzing Antibodies
The amidase antibody NPN43C9 that was described in section 2.1.5 has been
the antibody whose mechanism has been investigated most extensively. Initially,
Benkovic et al. analyzed the steady state parameters, kcat/Km and kcat as a function
of pH, and discovered that an apparent pKa of 9.0 was displayed for an ionizable
residue 51. This could be interpreted as either a reaction mechanism involving an
active site residue whose deprotonation promotes hydrolysis, or a mechanism
featuring a change in the rate-determining step around an intermediate antibody-
bound species, occurring as a function of pH. No isotope effect was observed for the
anilide 39 when the pH-kcat rate profile was measured in D20 which tends to rule
out the possibility of a general acid/base catalysis involving an active site residue in
the rate determining step.
Mechanism of NPN43C9 was also studied with the p-nitrophenol ester analog
of 39. Initially, no direct evidence for the formation of an antibody acyl covalent
intermediate could be found: no rapid formation of p-nitrophenol was observed; and
no exchange of 180 from H 2 180 into the substrate was observed 52 . The former
observation does not, however, rule out the possibility of an intermediate at steady
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state levels, and the latter does not eliminate the possibility of an asymmetrical
intermediate or again, steady state acyl species. Two mechanisms were considered
to account for the observations, one involving an active site nucleophile whose
reactivity was dependent on its pKa, and a second mechanism, where the pKa of the
active site nucleophile was outside of the observable pH range. The pH-rate profile
was explained by a change in the rate-determining step from p-nitrophenol release
at low pH to hydroxide mediated hydrolysis at high pH.
A second study on the same antibody NPN43C9 sought further evidence for
an acyl-antibody intermediate, by examining the antibody catalyzed hydrolysis of a
series of p-substituted phenyl ester substrate analogs 53. Hammett structure-
reactivity correlation studies indicated a mechanism involving nucleophilic attack
by a neutral nitrogen such as imidazole. On the basis of molecular modeling studies
which showed that one of two histidines in the antibody combining site might be in
the correct orientation for nucleophilic attack on the substrate, and chemical
modification studies with diethylpyrocarbonate which inactivated the catalyst, the
authors suggested that the substrate might be acylated by an antibody active site
histidine.
To further prove the existence of a imidazole-acyl intermediate in the
antibody binding site, a three dimensional computer simulation model of the
antibody 43C9 was constructed based on the previously-solved X-ray structures of
antibody heavy and light chains that displayed sequence homology to 43C954 .
Histidines L91 and H35 were identified as likely candidates for the imidazole
nucleophile, while arginine L96 was found to be situated ideally to stabilize the oxy-
anion tetrahedral intermediate. A phagemid expression system was developed for
the production of single-chain Fv of 43C9 in E. Coli.
Site-directed mutagenesis experiments using the above expression system
showed HisL91 and ArgL96 to be the active site residues responsible for catalysis.
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Mutation of these residues resulted in the loss of catalytic activity without
concomitant loss in substrate binding. On the other hand, a second histidine,
HisH35 was found to be structurally important for this antibody, as any mutation of
this residue resulted in the loss of both catalytic activity and binding ability.
Finally tyrosines L32 and H95 were mutated separately into histidines as the
modeling studies had indicated that these residues were in appropriate location to
act as general acid catalysts. Surprisingly, both mutations caused a decrease in the
catalytic activity, ostensibly pointing to the limitations of the molecular modeling
experiment. Furthermore, mutation of HisL91 to a more nucleophilic serine or
cysteine also decreased the catalytic activity.
The final proof for the antibody-acyl intermediate came from electrospray
mass spectroscopy studies where a covalently bound species of mass weight equal to
an acylated antibody was detected at pH 5.9 which represented 10% of the total
antibody55 . In the presence of the hapten, this species was not detected. Based on
the kinetics and mutation experiments, the authors concluded that at pH values
less than 9, the rate limiting step is the hydroxide ion mediated hydrolysis of the
acyl intermediate, while above this pH, the rate determining step becomes either
product release (p-nitrophenyl ester) or the formation of the acyl intermediate
(other esters and p-nitroanilide). Hence, the mechanism of 43C9 with ester
substrates can be summarized as follows: the attack of HisL91 on the substrate
carbonyl forms the acyl-histidine complex, while ArgL95 stabilizes the forming oxy-
anion tetrahedral intermediate. The liberated phenol remains bound to the
antibody. This intermediate is then hydrolyzed by hydroxide ion to give a ternary
complex of antibody, phenol and the acid. The two ligands are then released
sequentially to complete the catalytic cycle. The authors expressed their belief that
the nucleophilic catalysis displayed by antibody 43C9 had been generated
fortuitously and that further acid-base catalysts could be introduced by site-directed
mutagenesis.
The mechanism for the hydrolysis of phenyl acetate 66 by antibody 20G9
raised to hapten 67 was investigated by Martin et al.56 . In contrast to the above
esterolytic activity by NPN43C9, the hydrolysis of phenyl acetate by antibody 20G9
was characterized by a pre-steady state burst producing phenol. The latter was an
inhibitor of the antibody, where Kiapp = 2.5 gM. At pH 8.8, the initial kinetic
constants were kcat = 4.9 min -1 and Km = 300 gM, and at steady state kcat = 0.54
min -1 and Km = 36 gM. Examination of the pH rate profile indicated an active site
residue with a pKa = 9.6, and a constant value of Km over the pH range 7.0 - 11.0.
Phenol and phenolate were shown to inhibit the reaction equally which indicates
that the pH-rate profile depends on kcat (rather than any pH dependence for the
dissociation of the antibody-phenol complex). Finally, chemical modification studies
with tetranitromethane and affinity labeling reagents specific to phenols caused a
loss of activity. This led the authors to suggest that the mechanism of 20G9
involved an acyl-tyrosine intermediate in the binding site.
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Another valuable inquiry into the mechanism of action of esterolytic
antibodies came from the laboratory of Thomas Scanlan 57 . Phosphonate hapten 68
was used to generate an antibody 17E8 that catalyzed the hydrolysis of the phenyl
esters of norleucine (69a,b) and methionine (70a,b) 2.2 x 104 fold over the
background reaction at pH 7.2. In fact, at pH 9.5 where the antibody catalyzed
reaction is 20 fold faster, the comparative rate acceleration approaches 106 over the
water catalyzed reaction, which is one of the fastest ever reported. Greater than
1000 turnovers were also observed. This antibody was found to be selective for the
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(S) enantiomers of the substrates matching the conformation of the inducing
hapten, and displayed a bell-shaped pH optimum which indicated the participation
of two catalytic residues with pKa's 8.9 and 10.1.
0H ,0-H 0,,0
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It was found that this antibody displayed six fold selectivity for formylated
over acetylated substrates as well as a eight fold selectivity for norleucine over
methionine esters. The mode of catalysis was seen to involve the formation of a
covalent acyl intermediate with a binding site residue whose rate of formation was
the rate determining step. Thus when hydroxylamine was added to the reaction
mixture, a hydroxyamic acid product was also formed from the partitioning of the
acyl intermediate, while the overall rate of catalysis was not affected. It was
commented that the covalent intermediate might also be an oxazolone that is
formed by the intramolecular cyclization of the substrate. This would explain the
preference for the formylated over the acetylated substrates.
In a following paper the authors determined the X-ray structure of the Fab
fragment of this antibody bound to its hapten 58 . A protonated lysine (H97) was
found to form a salt bridge with the phosphonate pro-S oxygen. This lysine is then
a very likely candidate for the catalytic residue with a pKa of 10.1 which stabilizes
the oxy-anion of the transition state. Both the phenyl ring and the norleucine side
chains were found to be buried in hydrophobic pockets explaining the substrate
selectivity for norleucine over methionine esters. This finding supports the notion
that a phosphonate hapten can faithfully generate antibody residues to stabilize the
oxy-anion transition state of acyl hydrolysis. The identity of the pKa 8.9 residue
was more dubious, however. This pKa is in the right range for a tyrosine residue
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and Tyr H 1 0 1 was proposed to be a participant in catalysis. This residue acts as a
hydrogen bond donor to SerH 99 . Above pH 8.9, this tyrosine is deprotonated which
frees the serine to rotate 180 degrees and be in the correct position to attack the
acyl group of the substrate and form the observed acyl-intermediate. Furthermore,
it was speculated that this serine is also in the vicinity to form a hydrogen bond to
HisH35 similar to the catalytic triad of serine proteases.
Further indirect evidence for SerH99 as a nucleophile came from a
subsequent paper, where the four catalytic antibodies out of the total 20 that were
generated by hapten 68 were sequenced, including antibody 17E8 59. The second
most active antibody, 29G11 which is four-fold less active, displayed high structural
homology to 17E8 based on computer modeling. Interestingly, in this antibody,
SerH 99 was found to be replaced by GlyH99 and the formation of a covalent
intermediate was not observed by hydroxylamine partitioning studies. As 29G11
also displays a bell shaped pH optimum curve, the authors proposed that this
antibody functions by a general acid-base catalysis and HisH35 acts as the base to
deprotonate an incoming water molecule.
2.4.3 Remarks
The above information shows that nucleophilic catalysis is a powerful mode of
catalysis that previously had only been generated in catalytic antibodies by chance.
We considered the different possible methods of inducing a nucleophilic residue in
antibody binding sites, and it became apparent that a nucleophilic side chain
residue could not be generated via immunization. The only reliable method to
install such residues in antibody binding sites is via post-immunization
mutagenesis. Furthermore, in the few cases that this approach was taken, it was
seen to be labor - intensive as well as ineffective, since the engineered antibodies did
not have enhanced reactivity compared to the original clones 60.
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Thus, we decided that the only reliable method to incorporate nucleophilic
catalysis into antibody binding sites was to use an auxiliary catalyst. This is
possible either by the incorporation of such a residue into the substrate design, i.e.
intramolecular catalysis, or by bringing it in externally, similar to the use of co-
factors by enzymes. The following chapter is an account of a successful effort
wherein we have designed a reaction system and haptens that were flexible enough
to permit both methods of the use of an auxiliary nucleophile.
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Chapter 3
Catalytic Antibodies for Amide Hydrolysis
with an Auxiliary Nucleophile
3.1 Introduction61
Three haptens were designed and synthesized to incorporate three design
concepts that were conceived to be crucial for amide hydrolysis by antibody
catalysts: 1) the generation of bi-functional binding sites with the use of zwitterionic
charges; 2) the division of the zwitterionic charges into two haptens and the
employment of the previously shown heterologous immunization protocol; and 3)
incorporation of an auxiliary nucleophile to perform the initial nucleophilic attack
on the amide bond. An additional goal was to employ homologous immunizations
with each of the two haptens and compare the results with the heterologous
immunization regimen.
3.2 Hapten Design
Previous attempts at amide hydrolysis has relied on a water molecule to
diffuse into the antibody binding site and effect the nucleophilic addition to the
amide carbonyl. However, it is obviously difficult to program an antibody binding
site to selectively bind and orient a water molecule, and at the same time keep this
binding site accessible to an aqueous environment. Our approach was to replace the
water nucleophile with one that can be selectively recognized in aqueous solutions.
Hydrophobic interaction is a convenient recognition element, as these interactions
have been shown in X-ray crystallography studies of antibody-antigen complexes.
On the other hand, the low catalytic efficiencies of catalytic antibodies dictate that
this nucleophile should also be readily water-soluble. The combination of these two
criteria pointed to the selection of an aromatic nucleophile.
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A second point of consideration is that once this initial nucleophile has
cleaved the amide, the hydrolysis of this intermediate should also be facile,
completing the formal hydrolysis of the amide bond, and insuring against product
inhibition. In effect, we desired this auxiliary nucleophile to behave in a similar
fashion to enzymatic co-factors.
Phenol was chosen to be the auxiliary nucleophile as it fits all of the above
criteria well: 1) the phenyl ring can be bound tightly in a hydrophobic antibody
binding pocket; 2) the low pKa of phenol facilitates the removal of its proton by a
basic antibody residue; 3) it is readily soluble in water; and finally 4) phenyl esters
are easily cleaved in water.
A p-nitroanilide was chosen to be the substrate as the p -nitroaniline leaving
group is a good chromophore which ensures enhanced detection sensitivity for this
inherently slow reaction. This reaction mechanism is shown in Scheme 3.1.
Scheme 3.1
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With the selection of phenol and p -nitroanilide as the auxiliary nucleophile
and amide substrate, respectively, and also consideration of our previous experience
with esterolytic antibodies 39 ,49, the four essential features for a successful hapten
emerged: 1) an aromatic ring to generate the hydrophobic antibody binding pocket,
2) a positively charged residue placed in proximity of the location of the phenolic
hydroxyl. This should induce a basic residue in the antibody binding site to
deprotonate the phenol and subsequently protonate the departing amine. 3) a
negatively charged tetrahedral species such as a phosphonate or N-oxide to
represent the oxy-anionic tetrahedral intermediate, and finally, 4) the appropriate
disposition of the aromatic ring in relation to the amide by incorporation in a six
membered structure.
A pyridinium phosphonamidate hapten 71 then appears as the ideal
(hypothetical) hapten which can be bisected into haptens 72 and 73 according to our
heterologous immunization protocol 49. An N-oxide hapten 74 was also designed as
a replacement for 72, should the synthesis of the latter have posed a problem.
Initially, it was planned to also synthesize hapten 71 and compare the results of
immunization with this hapten with the heterologous immunization of 72 plus 73.
However, preliminary synthetic studies indicated that 71 would be an unstable
compound in aqueous solutions that are employed for immunizations 62.
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These six membered hapten structures also offered a hidden benefit.
Preliminary screens for catalysis could be performed with substrate 75 in an
unimolecular fashion. This avoids the difficulty of testing more than a hundred
potential antibody catalyst candidates in an initial bi-molecular screen, as each
antibody will have a different binding constant (or Km) to the two components of the
reaction. Thus conditions for each molecule, the phenol and the amide would need to
be optimized with each catalytic antibody candidate or an effective catalyst could
easily be overlooked. Clearly, this is a very laborious procedure. Substrate 75
provided an easy initial screen for catalysis. Once effective catalysts are identified
with 75, these can then be screened under the bimolecular conditions, with phenol
and propionic p-nitroanilide.
H
0
71
I
I
3.3 Synthesis of Haptens, Inhibitors and Substrates
The synthesis of the phosphonamidate hapten 72 is shown in Scheme 3.2.
Horner-Wittig olefination of benzyl protected salicaldehyde 76 with the methylene
biphosphonate 63 77 under biphasic conditions gave the styrylphosphonate 78 as the
pure (E)-isomer in good yield. Reduction of the olefin and removal of the benzyl
protecting group is then carried out in one step by catalytic hydrogenation to give the
saturated diethylphosphonate 79. At this point it was decided to cyclize 79 first and
subsequently install the labile phosphonamidate bond. One of the ethoxy groups of
the phosphonate 79 could easily be exchanged for chloride via reaction with PC15 , but
various reaction conditions failed to give the cyclized product. Generating the
monophosphonate and reacting with various acyl-coupling reagents such as BOP or
carbodiimides also failed to effect cyclization. The cyclization was finally realized
under acid catalyzed conditions with toluene-sulfonic acid. The optimization of
reaction conditions and the use of anhydrous toluene-sulfonic acid quickly achieved
two transformations in one pot giving the cyclized phosphonic acid 80 in 90% yield.
Scheme 3.2
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The formation of the phosphonamidate bond presented the greatest challenge
in this synthetic scheme. The phosphonyl chloride of 80 was found to be very
unreactive and failed to react with p-nitroaniline, aniline or even with a carbamate
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protected phenylenediamine under various reaction conditions. Only an excess
unprotected phenylenediamine showed the requisite nucleophilicity to add to this
unreactive phosphonyl chloride. The difficulty of handling excess phenylenediamine
was solved by a three step purification scheme that involved removal of the excess
phenylenediamine via sublimation, followed by two column chromatography steps to
yield the desired phenylenediamino-phosphonamidate 81. Coupling with glutaryl
anhydride afforded hapten 72.
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The N-oxide hapten 74 was conceived as an alternative to the
phosphonamidate hapten 72, since the N-oxide moiety also represents a tetrahedral
orientation with an oxy-anionic negative charge. However, the bond angles as well
as lengths are less suitable than phosphonate-type haptens in mimicking the
tetrahedral transition state of acyl transfer reactions. The synthesis of hapten 74
was straight-forward as shown in Scheme 3.3 with no problematic steps. Thus,
dihydroisoquinoline 82 was alkylated with p-nitrobenzylbromide followed by the
reduction of the nitro group to give 83. Coupling with glutaryl anhydride then
afforded compound 84. The tertiary amine of 84 was relatively unreactive towards
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oxidation to the N-oxide, and after testing various reagents and conditions including
different peroxides and dioxirane; m-CPBA was found to be the most effective
reagent giving hapten 74 in 57% percent overall yield.
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The synthesis of hapten 73 (Scheme 3.4) was carried out in 13 steps and 10.9%
overall yield by Mr. Roman Fleck 61. Substrate 75 was synthesized in one step by the
opening of dihydrocoumarin 85 with p- nitroaniline and trimethylaluminium (Scheme
3.5). All three haptens were individually coupled to carrier proteins Keyhole Limpet
Hemocyanine (KLH) and Bovine Serum Albumin (BSA) via the reaction of their
activated N-hydroxysuccinimide esters (72a, 73a, 74a) with the surface lysine residues
of these proteins. Successful conjugation was confirmed with UV spectrophotometry.
The KLH conjugates were used in the immunizations as this protein is known to induce
strong immune responses, BSA conjugates were used in the subsequent Enzyme
Linked Immuno Sorbent Assays (ELISA's) of the generated hybridomas.
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3.4 Homologous and Heterologous Immunizations
With each hapten-KLH conjugate, eight Balb/C mice each received a
subcutaneous injection of 100 gg of the hapten-KLH conjugate. The protein
suspensions of KLH- 72 and KLH-74 were injected as an emulsion in an Alum
adjuvant, while KLH-73 remained in solution and was injected as an emulsion in
RIBI adjuvant (MPL and TDM emulsion). Two weeks later, the same injections
were repeated. Seven days after the second injection, blood serum from each animal
was analyzed by ELISA for the strength of the immune response to their inducing
haptens.
All of the animals injected with KLH-72 and KLH-73 displayed strong
immune responses to their respective hapten-BSA conjugates (titers = 1 : 25,600),
weaker immune responses to KLH alone (titers = 1: 12,800) and no response to
BSA alone. These results indicated that antibodies had successfully been generated
to 72 and 73. On the other hand, animals injected with KLH-74 showed no
response to BSA-74 or BSA; while displaying adequate response to KLH (titers = 1:
6400). This result indicated that either 74 was a poorly immunogenic substance or
this hapten was degraded once it was injected into mice. These mice were discarded
and all subsequent investigations were continued with mice injected with KLH-72
or KLH-73.
For the homologous immunization protocol, four out of the eight mice from
each group (KLH-72 or KLH-73) received a final booster injection with the KLH
conjugate (100 gg) of the same hapten two weeks after the second injections. These
injections were delivered intravenously in the absence of adjuvants in sterile
phosphate buffered saline (PBS) solutions and proved to be quite stressful to the
animals. In half of the cases, immediate death ensued due to a severe seizure from
immunological shock. However, this is not an uncommon occurrence especially
when a strongly immunogenic antigen is used. The surviving animals were
sacrificed 3 days after the final boost in order to isolate B-cells from their spleens
and generate hybridomas.
For the heterologous immunizations, the remaining four animals from each
group were immunized with the KLH conjugate (100 gg) of the opposite hapten
using the same procedure and time schedule. It should be noted that the fatality
rate was lower in these cases of heterologous immunization. The reasons for this
remain unclear. After 3 days, 2 animals from each immunization regimen (72, 72,
73 and 73, 73, 72) were sacrificed to generate hybridomas.
3.5 Fusions and Generation of Hybridomas
Three days after the final boost, the animals were sacrificed, and their
spleens were harvested for B-cells. The single cell suspensions from each spleen
were fused with 5 x 107 653/HGPRT- myeloma cell with the aid of polyethylene
glycol (PEG), a cell membrane denaturant. Upon the removal of PEG, cells were
suspended in HAT selection media, plated into ten 96-well plates, and incubated in
a 370 C sterile incubator. Two weeks after the fusion, each well was checked by
ELISA for the presence of antibodies that bound either their respective hapten
(homologous immunization) or both of the haptens (heterologous immunization).
3.5.1 Homologous Immunizations
Seventy-one clones combined from two fusions were found to respond positive
to BSA-72 by ELISA. These were also checked for binding to BSA-73 and only 4
showed very weak cross-reactivity. These were each grown to 1 mL scale and put
into limiting dilution wherein they were diluted serially and the positive binders
from the most dilute sample were re-grown. This process insures that each cell line
originates from a single parent and is genetically homogeneous. Hence, each
selected cell line produces a single type of antibody, a so-called monoclonal antibody.
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Fifty-nine cell lines were found to grow and secrete BSA-72 binders after the first
round of limiting dilutions. These were put into a second round of limiting dilution
to ascertain monoclonality, and 55 monoclonal cell lines remained after the second
limiting dilution.
Eighty-two clones from two fusions were found to be positive to BSA-73 by
ELISA. None of these were found to bind to BSA-72. After two rounds of limiting
dilutions 54 monoclonal cell lines were isolated.
3.5.2 Heterologous Immunizations
In the heterologous immunization with 72, 72, 73 a total of about 200 cell
lines from two fusions were found to bind BSA-72. Of these 78 clones also
responded to BSA-73. These 78 clones were selected and put through two rounds of
limiting dilutions to assure monoclonality. 40 cell lines that were cross-reactive to
both haptens remained after the limiting dilution processes.
In the heterologous immunization with 73, 73, 72 no cell lines were found to
respond to BSA-73 from 2 combined fusions. 40 cell lines did respond weakly to
BSA-72. All of these were later found to be of the sub-type IgM, representing a
primary immune response to 72. As this is not suitable for the purposes of
heterologous immunization, these cell lines were discarded. The reasons for this
interesting phenomenon remain unclear but most probably reside in the
requirements for the cross-reactive stimulation of memory B-cells. A similar
observation has also been made in our previous study of heterologous
immunization 31.
3.6 Antibody Production and Purification
The cell lines that remained at the end of two rounds of limiting dilutions
were each grown to 10 mL scale and to >95% viability (percentage number of viable
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cells). At this point 5 x 106 cells from each were transferred to 1 mL of 8% DMSO in
Fetal Bovine Serum (FBS) solution and stored initially at -80 oC for four months
after which they were transferred to -180 'C. These frozen stocks are then stable
indefinitely and can be re-grown upon proper thawing.
Another 1.5 x 106 cells were injected in PBS into the intraperitonal cavity of
Balb/C mice which had been primed with pristane. The pristane priming induces
plasmocyte formation of the injected hybridomas. An ascitic fluid is produced which
is enriched (up to 10 mg/mL) in antibodies. This was isolated from the
intraperitonal cavity via three taps with a hypodermic needle.
A three step protocol was used to purify each monoclonal antibody.
Precipitation with ammonium sulfate (at 45% final concentration of saturated
solution) was followed by DEAE anion exchange chromatography. The fractions
containing the antibody were pooled and re-purified via protein G affinity column
chromatography. Protein G is a bacterial protein that binds to the constant region
of most subtypes of mouse antibodies with high specificity.
Collected antibody fractions were quantified via the constant UV absorption
of their tryptophan residues at 280 nm. Each antibody solution was then exchanged
into 10 mM PIPES buffer at pH 6.8 with 0.1% sodium azide to inhibit bacterial
growth. These were concentrated to 6 mg/mL concentration and were stored at 4 oC
until they were assayed in the appropriate reaction buffer (at 50 mM assay buffer
concentration at the final pH)
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3.7 Amide Hydrolysis Assay with Unimolecular Substrate 75
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Initial assays were performed at two different pH's (50 mM PIPES, 80 tM
NaC1, pH 6.8; 50 mM CHES, 80 iM NaC1, pH 9.0). High Performance Liquid
Chromatography (HPLC) was used to separate Substrate 75 from products
dihydrocoumarin and p-nitroaniline with 45% acetonitrile (AcN), 0.1%
trifluoroacetic acid in H 2 0 as the isocratic eluent. The reactions were followed by
monitoring the appearance ofp-nitroaniline at 382 nm (absorption maximum). 50
gM 4-Phenylazophenol was used as the internal standard to calibrate against
variance in injection volumes.
Of the 55 hybridoma clones raised to 72, only 39 yielded sufficient quantities
of antibody to screen for catalysis. After the initial screens, 2 out of the 39 were
found to be catalytic. The more efficient catalyst 6-17 was characterized further. It
was found to obey Michaelis-Menten kinetics with a kcat = 1.8 x 10- min-1 and Km =
0.86 mM at pH 6.8. It was inhibited competitively by hapten 72 with a Ki = 36 RM.
As expected, no inhibition was seen with hapten 73. This antibody displayed a pH
optimum at 8.0 (vide infra) where kcat = 2.7 x 10-3 min -1 and Km = 0.98 mM. The Ki
at pH 8.0 could not be determined due to the instability of hapten 72 at this pH,
although competitive inhibition was seen.
Twenty out of the 54 monoclonal clones generated to hapten 73 yielded
sufficient quantities of antibody to screen, and one, 3-49, was found to be a catalyst.
The catalytic efficiency of this antibody increased with increasing hydroxide
concentration (vide infra) and its Michaelis-Menten parameters were determined at
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pH 9.0 (kcat =4.2 x 10-3 min-1, Km = 0.77 mM). It was also shown to be competitively
inhibited by its respective hapten 73 (Ki = 380 gM), while no inhibition was seen
with hapten 72.
Fifteen out of the 40 monoclonal antibodies generated by the heterologous
immunization (72, 72, 73) were of screenable quantity and 3 were found to be
catalytic. The most efficient catalyst 14-10 was characterized by Michaelis Menten
kinetics. At pH 6.8 kcat = 0.0093 min-1 and Km = 1.40 mM. In accord with its
binding affinity to both haptens, the catalytic activity of this hapten was
competitively inhibited by both 72 (Ki = 51 gM) and 73 (Ki = 790 gM). This antibody
displayed a bell shaped pH optimum curve hinting at two ionizable binding site
residues that participate in catalysis and displayed a pH optimum at pH 8.0 (vide
infra). At this pH, kcat = 0.015 min- 1 and Km = 1.27 mM. As in our previous studies
with esterolytic antibodies, antibody 14-10 generated by heterologous immunization
is an almost ten-fold more efficient catalyst than its homologously generated
counterparts.
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The background rate of hydrolysis of amide 75 at pH 6.8 was measured to be
4.7 x 10- 7 min-1.64 Interestingly, the background hydrolysis reaction of the phenyl
substrate 86 was found to be almost identical (4.8 x 10- 7 min- 1) showing that under
aqueous conditions the phenol group does not participate in an intramolecular
catalysis. This is to be expected as substrate 75 should preferentially exist in an
extended conformation leaving its phenolic group at a severe entropic disadvantage
to compete with the solvent water molecules, either as an intra-molecular proton-
donor or a nucleophile.
The evidence for the intramolecular participation of the phenol of 75 in the
antibody catalyzed reaction came from the studies with substrate 86. None of the
three antibody catalysts accelerated the observed hydrolysis of 86. This shows that
the phenol moiety is required for antibody catalysis. Based on the design of the
inducing haptens, it seems likely that this phenol acts as a nucleophile generating
dihydrocoumarin and releasing p-nitroaniline. Dihydrocoumarin was observed to be
a weak competitive inhibitor for all three catalysts although inhibition constants
could not be determined due to the relatively facile rate of hydrolysis of
dihydrocoumarin at pH 8.0 - 9.0.
The kinetics of the antibody-catalyzed hydrolysis of dihydrocoumarin was not
investigated, as more direct evidence for the intramolecular participation of phenol
was obtained from the studies of the targeted inter-molecular reaction. All three of
the catalytic antibodies were found to catalyze the cleavage of propionyl p-
nitroanilide 87 with phenol.
3.8 pH-optimum Studies
The pH-optimum of the three catalytic antibodies were investigated at pH
6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0 with the three component buffer MHD (12.5 mM MES,
12.5 mM HEPES, 25.0 mM Diethanolamine). Due to limited quantity of the
antibodies, kcat and Km's were not be determined at every pH value. Two types of
pH dependency were observed. Antibody 3-49 displayed an almost-linear
dependency on pH with a steep slope which hints that hydroxide ion concentration
is a major component of the rate equation for the antibody catalyzed reaction.
Ab 3-49 pH-optimum
5.5 6 6.5 7 7.5 8 8.5 9 9.5
.............
!.............. T.............. ".:............ .. • ...........
.............. .............. ...............* ...........
I I.............. ......... ............. ...........
i
5.5 6 6.5 7 7.5 8 8.5 9 9.5
pH
Both 6-17 and 14-10 displayed bell shaped reaction-rate vs. pH curves with
an optimum pH of action at 8.0. It is tempting to speculate that these plots reflect
the presence of two ionizable residues of each antibody that participate in the
catalysis. However, such claims should only be made after careful plots of kcat vs.
pH or kcat/Km vs. pH. These two plots are nonetheless encouraging as our initial
aim was to generate bi-functional binding site residues in the antibody catalysts.
Further studies with bi-molecular amide hydrolysis were performed at pH 8.0 as
this appeared to the optimal pH for at least two of the catalytic antibodies.
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3.9 Cleavage of Propionyl p-Nitroanilide with Phenol
0
OH O
Substrate 87
H2 0Ro
o0  OH OAOH
Assays were carried out at pH 8.0 using the three component buffer MHD.
HPLC was used to follow the appearance of p-nitroaniline (35% AcN, 0.1%
trifluoroacetic acid in H 2 0 as the isocratic eluent). The reactions were followed at
382 nm, and 50 gM 4-phenylazophenol was used as the internal standard.
Antibodies 3-49, 6-17 and 14-10 were assayed for the acceleration of the
cleavage of propionyl p-nitroanilide in the presence of 10 fold excess of phenol at pH
8.0. All three antibodies were found to accelerate this reaction and their Michaelis-
Menten parameters were determined. The heterologously generated antibody 14-10
was again the most efficient catalyst with kcat = 1.33 x 10-4 min-1 at pH 8.0. For
phenol Km = 136 gM and for 87 Km = 370 gM. Both haptens were shown to
effectively inhibit the reaction.
6-17 was the next most efficient catalyst with kcat = 2.1 x 10-5 min-1 . The
Michaelis constants KmPhenol = 78 gM and Km87 = 310 gM were observed. This
antibody was competitively inhibited by its respective hapten, 72 while no inhibition
was seen with 73.
3-49 was the slowest catalyst with kcat = 1.28 x 10-5 min-1 . Interestingly, it
also displayed the smallest Michaelis constants, KmPhenol = 14 gM and Km87 = 77
gM. Hapten 73 effectively inhibited the observed catalysis with 3-49 while no
inhibition with hapten 72 was observed.
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Figure 3.1 Woolf-Hofstee Plots of 14-10 for Phenol and Amide 87
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Assay Conditions: 1 gM Antibody; 62.5, 125, 250, 500, 1000 gM phenol; 125, 250, 500,
1000, 3000 pM 87; pH 8.0; MHD buffer. (y= Vmax - Km * x).
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Figure 3.1 Woolf-Hofstee Plots of 6-17 for Phenol and Amide 87
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Figure 3.1 Woolf-Hofstee Plots of 3-49 for Phenol and Amide 87
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The participation of phenol in antibody catalysis was proven beyond doubt
with a simple control experiment. In the absence of phenol, all three antibodies
showed no acceleration of the cleavage of amide 87. Furthermore, neither 2-napthol
(88) nor 4-tert-butyl phenol (89) were accepted for catalysis by any of the three
catalysts. These results indicate the existence of a dedicated binding pocket for the
phenol auxiliary nucleophile. Similarly, these catalysts were also shown to be
specific for propionyl anilide. t-butyl-acetyl p -nitroanilide (90) was not accepted as a
substrate, indicating that a dedicated and specific binding pocket also exists for the
amide 87. Together with the observation that phenyl propionic amide 86 was not
subject to antibody catalysis, these results confirm that the participation of phenol
is essential for the antibody catalyzed cleavage of amide 87.
KH OH N H4NO2
88 89 90 91
Finally, the product phenyl propionate (91) did not inhibit the antibody
catalyzed cleavage of 87 even at relatively high concentrations (5 mM 91 and 0.5
mM 87) indicating that the product 91 efficiently diffuses out of the antibody
binding site upon formation. Furthermore, none of the three antibodies displayed
significant acceleration of the hydrolysis of 91.
The background rate for the hydrolysis of amide 87 was found to be 2.1 x 10-7
min -1 at pH 8.0. However, this rate can not be directly compared with the kcat's
above as the antibody catalyzed reaction requires the participation of phenol, while
the uncatalyzed rate of cleavage of amide 87 is not accelerated by the addition of
phenol.
It is important to note that the order of catalytic efficiency among the three
catalysts reflects the pattern seen with the unimolecular substrate 75, despite the
fact that the Michaelis constants are varied for the three antibodies. This supports
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the notion that catalytic efficiency by antibodies is independent of the efficiency of
substrate binding but rather depends on transition state binding and the
participation of optimally placed catalytic residues.
All of the Km's for the bi-molecular reaction were smaller than the Km's for
the unimolecular substrate 75. This can be explained by the mismatch between the
expected conformation of 75 and the conformation of the inducing haptens. In
aqueous solutions, the carbonyl and the phenol of 75 should be far removed in an
extended conformation, whereas in the haptens these two moieties are in close
proximity. Therefore, it is likely that the binding of 75 by these antibodies proceeds
in two steps with either the phenol or the carbonyl being bound first, followed by the
second portion of the substrate as it motions into the correct orientation in the
antibody binding cavity.
Another point of consideration is that the Km's for phenol were smaller than
the Km's for 87. This can be rationalized by the placement of the phenol away from
the glutaric acid linker portion in the hapten designs. Therefore, it is likely that the
phenol is bound in a deep pocket in the antibody binding sites while the binding
pocket for 87 is more solvent accessible. The observation of small Km's for phenol by
the three antibodies is also a subtle vindication of our choice of phenol as the
external nucleophile. Interestingly, at high concentrations ( > 10 mM) phenol was
seen to inhibit the bi-molecular reaction. This can be a result of phenol starting to
compete with 87 for its binding pocket at such high concentrations. This could also
be a point of improvement for the future designs of auxiliary nucleophiles in
antibody catalysis, i.e. the effective differentiation of auxiliary binding from
substrate amide binding.
The lower kcat's displayed by the three antibodies towards amide 87 as
compared with 75 could be stemming from three reasons: The six membered
structure of 75 might be bestowing a more optimal attack angle for phenol to the
carbonyl than can be provided by antibody binding alone as in the case of 87 and
phenol. Alternatively, the formed tetrahedral intermediate 75a could be forced by
antibody binding to expel the amide more preferentially than 87a where there is
more rotational freedom available. A similar argument is that in 87a the amine is
less optimally placed in the binding site for its protonation by a hydrogen donor.
Finally, the ortho hydrogen of phenol could be experiencing a steric repulsion from
the B-hydrogens of the propionate as the hapten structures represent this
interaction with a carbon-carbon bond.
OIHN>NO2 o "S HOHN--
75a 87a 87b
Perhaps the most important aspect of the antibody catalyzed cleavage of 87 is
that the background rate of hydrolysis (2.1 x 10-7 min -1) of 87 decreases with an
increasing amount of phenol that is present in the medium. This is in accord with
the expected mechanism of the uncatalyzed reaction with water where the expulsion
of the p-nitroaniline from the tetrahedral intermediate 87b is the rate determining
step. Given that the phenoxide is a better leaving group than hydroxide ion, it is
expected that the rate of amide expulsion from 87b is greater than that from 87a.
Increasing the amount of phenol in the uncatalyzed reaction results in an increase
in the formation of 87a compared to 87b and accordingly, a decrease in the observed
rate of hydrolysis of 87.
Given that the rate of hydrolysis of 91 (1.1 x 10-4 min -1) is three orders of
magnitude faster than the rate of hydrolysis of amide 87, and that 91 appears to
freely diffuse out of antibody binding site (i.e. no product inhibition is seen with 91),
it can be said that all three antibodies have, in-effect, achieved the hydrolysis of the
amide bond of 87, with the rate determining step of the overall transformation
being the formation of 91 from 87.
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3.10 Conclusion
We have shown here a novel approach to the hydrolysis of amide bonds with
antibody catalysts. Phenol was used as an external nucleophile to aid in the
cleavage of an amide bond. Furthermore, our heterologous immunization method
has been shown to generate a more efficient catalyst (14-10) than either of the two
homologous immunizations. This is in accord with our previous report with
esterolytic antibodies where heterologous immunization was seen to result in a 100
fold more efficient antibody catalysis 49. Although the achieved rate acceleration of
the bi-molecular reaction is low, the significance of the catalysis rests on the high
energy of activation that is inherent in cleaving amide bonds, as well as the lack of
phenol participation in the reaction in the absence of the antibody catalysis.
Two paths can be taken to improve the rate acceleration with this present
approach: First, different nucleophiles can be examined instead of phenol, such as
imidazole or pyridine. Second, the protonation of leaving amine of the tetrahedral
intermediate can be further stressed by appropriate hapten designs. Finally, this
design concept, catalysis by external nucleophiles, can also be applied to other
hydrolysis reactions, such as glycolysis or phosphodiester hydrolysis. A similar
mechanism with the use of the 2' hydroxyl is already known to be used in the
cleavage of RNA by RNAse's.
3.11 Perspectives
As accumulating evidence indicates that efficient antibody catalysis requires
more than simple preferential binding to the transition state (and thus, to the
transition state analog hapten), it is desirable to incorporate a screen for catalysis
as early in the search for catalytic antibodies as possible. It is rather expensive in
time, money and effort to generate 150 monoclonal antibodies that initially
displayed affinity to a hapten only to isolate 3 catalysts! An alternative approach
termed catELISA has been reported 65 that screens directly for catalysis in the first
ELISA screen after the fusion. Instead of detecting antibodies bound to an
immobilized hapten, the catELISA method screens for the presence of a reaction
product, after antibodies have been incubated in the presence of immobilized
substrates.
Research in the Masamune group will incorporate catELISA techniques to
the presently demonstrated auxiliary nucleophilic catalysis method to isolate
antibody catalysts that achieve novel transformations of therapeutic and theoretical
importance.
Chapter 4
Experimental
4.1 Synthesis of Haptens and Substrates
4.1.1 General Methods
All reactions were carried out in oven-dried glassware under an argon
atmosphere unless otherwise noted. Aqueous reactions were run under ambient
atmosphere. Column chromatography was performed using 230-400 mesh silica gel
(Merck). Proton (1H NMR) magnetic resonance spectra were recorded at 300 MHz
on a Varian XL-300 instrument. The chemical shifts of 1H NMR spectra were
referenced to CDC13 (7.24 ppm), DMSO (2.49 ppm), CD 2 Cl2 (5.32 ppm), or CD 3OD
(3.30 ppm). 1H NMR peak multiplicities are reported as follows: s (singlet), d
(doublet), t (triplet), q (quartet), quint (quintuplet), m (multiplet), br (broad).
Coupling constants (J) are reported in Hz. Proton-decoupled-carbon (13C NMR) and
phosphorus (31P NMR) magnetic resonance spectra were recorded at 75.44 MHz
and 121.44 MHz on a Varian XL-300 instrument. The chemical shifts of 13C NMR
spectra were referenced to CDCl3 (77.0 ppm), DMSO (39.5 ppm), CD 2C12 (53.8 ppm),
or CD 3 OD (49.0 ppm). 31P NMR spectra were referenced to 85% H3 PO2 as an
external standard (capillary tube within NMR tube). Infrared (IR) spectra were
recorded on a Perkin-Elmer 283B spectrometer. Melting points were not corrected.
High-resolution mass spectra (HRMS) were recorded on a Finnigan MAT 8200
spectrometer. Reagents were used as supplied by the vendors, except in moisture
sensitive reactions where reagents were dried CH 2Cl2 (over Na), THF (over Na) and
Pyridine (over CaH2). The following abbreviations are used: DMSO
(dimethylsulfoxide), AcN (acetonitrile), MeOH (methanol), THF (tetrahydrofuran),
EtOAc (ethylacetate), DMAP (dimethylamino pyridine), EDC (1-(3-
Dimethylaminopropyl)-3-ethylcarbodiimide), rpm (rounds per minute).
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4.1.2 Synthesis of Hapten 72
OCHHO Br 
C1ý HO0
'cc0  
~Q0c'S ~adeK:2CO3O
Salicaldehyde K2C0 3  76
Benzyl protection of salicaldehyde 66 :
A mixture of 300 mL of MeOH, 600 mL of CHCl3, and anhydrous K2CO3
(29.9 g, 216 mmol) was refluxed for 15 min under a stream of argon before
salicaldehyde (5.25 mL, 49.1 mmol) and benzyl bromide (6.45 mL, 54 mmol) were
added, and the mixture was refluxed for 1 day. After filtration, the filtrate was
evaporated, and the residue was dissolved in CH2Cl2, washed with 1N HC1, dried
over MgSO4 and concentrated in vacuo to give 76 (10.3 g, 98.8 %) as a slightly
yellow oil. 1H NMR of the crude showed it to be sufficiently pure and it was used in
the next step without any further purification.
Physical Data:
1H NMR (300 MHz, CDC13): 8 10.57 (s, 1 H), 7.86 (d, J = 8.0 Hz, 1 H), 7.57-7.49 (m,
1 H), 7.47-7.32 (m, 5 H), 7.08-7.00 (m, 2 H), 5.19 (s, 2 H)
IR (film): 3053, 3020, 2751, 1687, 1598, 1480, 1462, 1374, 1284, 1236, 1187, 1155,
1100, 1014, 911, 851, 829, 753, 693, 655.
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Horner-Wittig coupling of 76 with tetraethylmethvlene bisphosphonate:
To benzyl-salicaldehyde ether 76 (0.74 g, 3.48 mmol) and bisphosphonate 77
(0.86 mL, 3.48 mmol) in 6 mL of CH 2 Cl2 was added 6 mL of 50% NaOH, and the
biphasic reaction was stirred vigorously open to ambient athmosphere for 4 hours.
The reaction mixture was diluted with 20 mL of water and extracted twice with
20mL of CH 2 Cl2 . The organic layers were combined, dried over MgSO4, and
concentrated in vacuo to afford styrylphosphonate 78 as a colorless oil (1.1 g, 92%)
Physical Data:
1 H NMR (300 MHz, CDC13): 8 7.88 (dd, JP-H = 23.4 Hz, JH-H = 17.7 Hz, 1 H), 7.46
(dd, J = 4.8, 1.5 Hz, 1 H), 7.41-7.21 (m, 6 H), 6.92 (t, J = 9.0 Hz, 2 H), 6.32 (dd, JP-H
= 19.5 Hz, JH-H = 17.7 Hz, 1 H), 5.19 (s, 2 H), 4.07 (quin, J = 7.2 Hz, 4 H), 1.28 (t, J
= 7.2 Hz, 6 H)
13C NMR (75.44 MHz, CDCl3): 8 154.26, 143.85 (d, JC-P = 117.2 Hz), 141.16 (d, JC-P
= 11.1 Hz), 133.46, 131.65, 128.67, 128.45, 128.29, 127.64, 126.97, 126.63, 122.82,
63.27, 62.10 (d, JC-P = 4.9 Hz), 31.78
IR (film): 3209, 2977, 2745, 2612, 1594, 1500, 1456, 1378, 1224, 1041, 970, 865, 754.
HRMS (M+): Calcld 346.3630 Found 346.3629
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Reduction and deprotection of stvrylphosphonate 79 via catalytic hydrogenation:
To styrylphosphonate 78 (1.99 g, 5.72 mmol) in 30 mL of EtOH was added a
catalytic amount of 10% Pd/C. The mixture was shook under 50 psi of H2 for three
days, filtered through celite and concentrated in vacuo to yield the phenol
diethyphosphonate 79 (1.45 g, 98%) as a colorless oil. This was used in the next
step without further purification.
Physical Data:
1H NMR (300 MHz, CDCl3 ): 8 8.45-8.10 (br, 1 H), 7.10-7.02 (m, 2 H), 6.88 (d, J = 8.2
Hz, 2 H), 6.78 (t, J = 7.8 Hz, 2 H), 3.99 (quin, J = 7.2 Hz, 4 H), 2.89 (dt, jP-H = 22.8
Hz, jH-H = 7.2 Hz, 1 H), 2.12 (dt, JP-H = 17.1 Hz, JH-H = 7.2 Hz, 1 H), 1.33 (t, J = 7.2
Hz, 6 H)
13C NMR (75.44 MHz, CDC13): 5 131.67, 130.84, 128.59, 128.19, 126.63, 121.52,
62.10 (d, JC-P = 4.8 Hz), 31.78, 25.56 (d, jC-P = 11.5 Hz), 20.45 (d, jC-P = 125.6 Hz)
31p NMR (121.44 MHz, CDC13): 5 45.58
HRMS (M+): Calcld 258.2542 Found 258.2537
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De-esterification and cyclization of the phenol diethylphosphonate 79 to cyclic
phosphonic acid 80:
Phenol diethyphosphonate 79 (1.8 g, 6.97 mmol) and anhydrous
toluenesulfonic acid ( 1.57 g, 9.07mmol) in 40 ml of xylene were refluxed under
ambient atmosphere for 24 hours. The reaction mixture was cooled to room
temperature, concentrated in vacuo to a volume of 3-4 mL and cooled to 5 oC
overnight. Cyclic phosphonic acid 80 (1.15 g, 90%) was collected as a white solid
precipitate. This was found to be pure by 1H NMR and used without further
purifications. It can be recrystallized from acetone for analytical purposes.
Physical Data:
1 H NMR (300 MHz, DMSO: 8 7.29-7.16 (m, 2 H), 7.12-6.98 (m, 2 H), 3.04 (dt, jP-H =
23.6 Hz, JH-H = 7.4 Hz, 2 H), 2.12 (dt, JP-H = 17.9 Hz, JH-H = 7.4 Hz, 2 H)
13C NMR (75.44 MHz, DMSO): 8 129.77, 129.46, 128.70, 127.69, 124.94, 119.28 (d,
jC-P = 7.5 Hz), 32.47 (d, jC-P = 9.8 Hz), 28.02 (d, JC-P = 107.9 Hz)
31p NMR (121.44 MHz, DMSO) 8 25.76
HRMS (M+): Calcld 184.1314 Found 184.1311
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Coupling of phenylene diamine to the cyclic phosphonic acid 80 via its phosphoryl
chloride to yield 81:
Cyclic phosphonic acid 81 (1.150 g, 6.3 mmol) and PC15 (2.0 g, 9.6 mmol) were
suspended in 10 mL of dry CH 2C12 and refluxed overnight. Xylene was added and
the mixture was concentrated in vacuo. Azeotropic removal removal of xylene was
repeated a number of times to remove the POC13 by-product of the reaction.
The phosphonyl chloride (0.77 g, 3.8 mmol) was redissolved in 10 mL of dry
CH 2C12 and added dropwise over 1 hour via an addition-funnel to a solution of
freshly-sublimed phenylene diamine (0.87 g, 8.0 mmol), dry pyridine (0.67 mL, 8.0
mmol) and DMAP (cat.) in 2 mL of dry DMF. The reaction was stirred for another 6
hours at room temperature. After the addition of 40 mL of CH 2 012, the precipitated
pyridinium chloride was removed by filtration, and the filtrate was concentrated in
vacuo. Excess unreacted phenylene diamine was removed by sublimation in vacuo
(1mm Hg, 120 oC) and the remaining residue was dissolved in MeOH, coated onto
silica gel and purified via column chromatography (2-5% gradient methanol in
CH 2C12 ). The fractions containing the product 81 with the contaminating
phenylene diamine were then pooled, concentrated in vacuo, re-dissolved in
methylene chloride, coated onto silica gel and purified again by column
chromatography (75-100% EtOAc gradient in Hexane with 0.1% NH 4OH) to yield
product 81 (0.364 g, 35%) as an off-white solid. This compound is stable indefinitely
in ambient atmosphere.
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Physical Data:
1 H NMR (300 MHz, CD3OD): 8 7.26-7.12 (m, 2 H), 7.08-6.94 (m, 4 H), 6.80 (d, J = 8.4
Hz), 3.18-3.02 (m, 2 H), 2.27-2.11 (m, 2 H)
13C NMR (75.44 MHz, DMSO): 8 150.89 (d, JC-P = 6.6 Hz), 136.53, 132.62, 128.64,
127.70, 124.15 (d, JC-P = 10.4 Hz), 123.32, 120.96 (d, JC-P = 5.5 Hz), 118.30 (d, jC-P
= 6.9 Hz), 118.15, 23.93 (d, JC-P = 9.3 Hz), 20.52 (d, JC-P = 115.9 Hz).
31p NMR (121.44 MHz, DMSO): 8 27.16
HRMS (M+): Calcld 274.2591 Found 274.2592
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Preparation of Hapten 72:
A mixture of phosphonamidate 81 (0.215 g, 0.785 mmol) and glutaryl
anhydride (0.99 g, 0.86 mmol) in 20 mL of dry CH 2Cl2 were stirred at room
temperature for 3 hours. The product 72 (0.275 g, 91%) precipitated as a white solid
and was isolated via filtration. It was shown to be pure by 1H NMR and HPLC
analysis and can be stored indefinitely under ambient atmosphere. It was found to
be acid-labile in organic solvents and both acid- and base-labile in aqueous
solutions. It was shown to be stable for at least two weeks in pH 7.0 phosphate
buffer.
Physical Data:
1H NMR (300 MHz, CD3OD): 8 7.36 (d, J = 9.6 Hz, 2 H), 7.21-7.13 (m, 2 H), 7.04-6.95
(m, 4 H), 3.20-3.02 (m, 2 H), 2.35 (t, J = 7.5 Hz, 2 H), 2.34 (t, J = 7.5 Hz, 2 H), 2.24-
2.11 (m, 2 H), 1.94 (quin, J = 7.2 Hz, 2 H)
13C NMR (75.44 MHz, CD3OD): 5 176.39, 172.76, 152.08 (d, jC-P = 8.0Hz), 136.13,
134.02, 129.91, 129.00, 125.31 (d, JC-P = 12.7 Hz), 124.62, 122.08, 120.26 (d, JCP =
5.7 Hz), 119.68 (d, JC-P = 6.9 Hz), 36.45, 33.77, 25.18 (d, jC-P = 8.1 Hz), 21.80 (d, JC-
P = 114.3 Hz), 21.58
31p NMR (121.44 MHz, CD3 OD): 8 27.49
HRMS (M+): Calcld 388.3600 Found 388.3598
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Preparation of N-hydroxysuccinimide activated 72a:
A mixture of phosphonamidate 81 (0.05g, 0.182 mmol), N-
hydroxysuccinamide glutary chloride (0.07g, 2.01mmol) and pyridine (25 gL, 0.3
mmol) in 5 mL THF were stirred for 1 hour. The pyridinium chloride precipitate
was removed by filtration. The filtrate was concentrated in vacuo, and purified by
column chromatography (2-5% MeOH in CH 2Cl2 ) to afford 72a (0.05 g, 47%) as a
white solid.
Physical Data:
1H NMR (300 MHz, CD 2C12 ): 8 8.21 (s, 1 H, H5 ), 7.36 (d, J = 8.8 Hz, 2 H, H6 ), 7.24
(t, J = 7.5 Hz, 1 H, HO10), 7.16 (d, J = 6.0 Hz, 1 H, H9), 7.08 (d, J = 7.2.Hz, 1 H, H12),
7.02 (t, J = 5.7 Hz, 1 H, H11), 6.95 (d, J = 8.8 Hz, 1 H, H7 ), 6.47 (d, jP-H= 7.5 Hz, 1
H, H8 ), 3.24-3.01 (m, 2 H, H14), 2.97 (s, 4 H, Hi), 2.65 (t, J = 7.2 Hz, 2 H, H2 ), 2.40
(t, J = 7.2 Hz, 2 H, H4), 2.20 (dt, JP-H= 15.3 Hz, J = 7.8 Hz, 2 H, H13), 2.07 (quin, J
= 6.9 Hz, 2 H, H3 )
13C NMR (75.44 MHz, CD2 Cl 2): 8 176.47, 172.71, 170.10, 151.70 (d, JC-P = 6.7 Hz),
135.30, 133.87, 129.73, 128.77, 124.85 (d, JC-P = 27.0 Hz), 124.36, 121.69, 120.16 (d,
jC-P = 14.5 Hz), 119.39 (d, jC-P = 16.7 Hz), 35.56, 33.23, 30.29, 24.97 (d, jC-P = 8.2
Hz), 22.05 (d, JC-P = 140.3 Hz), 21.93
31p NMR (121.44 MHz, CD2C12): 8 26.90
4.1.2 Synthesis of Hapten 74
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Alkylation of dihydroisoquinoline with p-Nitrobenzyl bromide:
To a stirred suspension of 80% NaH (0.5 g, 16.5 mmol) in 20 mL THF was
added dihydroisoquinoline (1.9 mL, 15 mmol) dropwise via a syringe and stirred at
room temperature for 3 hours. A solution of p-nitrobenzyl bromide (3.24g, 15 mmol)
in 20 mL of THF was added dropwise and the reaction mixture was stirred
overnight at room temperature. The reaction mixture was filtered and concentrated
in vacuo. Purification by column chromatography afforded 82a as a yellow solid
(3.76 g, 94%)
Physical Data:
1H NMR (300 MHz, CDC13 ): 8 8.83, (d, J = 8.7 Hz, 2 H), 7.58 (d, J= 8.7 Hz, 2 H),
7.20-7.05 (m, 3 H), 7.00-6.95 (m, 1 H), 3.77 (s, 2 H), 3.65 (s, 2 H), 2.92 (t, J= 6.0 Hz, 2
H), 2.67 (t, J = 6.0 Hz, 2 H).
13C NMR (75.44 MHz, CDCl 3): 5 146.48, 134.32, 134.05, 129.37, 128.71, 126.48,
126.30, 125.72, 123.57, 77.44, 77.01, 76.57, 61.83, 56.06, 50.81, 29.06
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Reduction of the nitro group of 82a to amine:
A mixture of nitrobenzyl isoquinolie 82a (1.67 g, 6.23 mmol), 10% Pd/C (cat.)
and hydrazine hydrate (1.0 g, 20 mmol) in 20 mL of isopropyl alcohol was refluxed
for 24 hours. After cooling, the solution was decanted, concentrated in vacuo and
purified by column chromatography to give aminobenzyl isoquinoline 83 (1.27 g,
86%) as a white solid. It can be recrystallized from acetonitrile for analytical
purposes.
Physical Data:
1H NMR (300 MHz, DMSO): 8 8.27 (s, 1 H), 8.19 (s, 1 H), 7.13 (d, J = 8.4 Hz, 2 H),
7.10-7.02 (m, 3 H), 3.52 (s, 2 H), 3.32 (s, 2 H), 2.78 (t, J = 6.1 Hz, 2 H), 2.64 (t, J=
6.1 Hz, 2 H)
13C NMR (75.44 MHz, DMSO): 8 151.12, 134.96, 134.23, 129.65, 129.08, 128.84,
128.44, 126.33, 125.92, 125.84, 125.41, 112.61, 61.81, 55.36, 50.11, 28.76
IR (film) 2902, 2799, 2352, 1600, 1496, 1462, 1416, 1392, 1366, 1312, 1262, 1236,
1140, 1086, 1056, 1016, 838, 808, 738.
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Addition of glutaric acid linker to aminobenzyl isoquinoline 84:
A solution of aminobenzyl isoquinoline 83 (1.0 g, 4.2 mmol) and glutaryl
anhydride (0.57 g, 5 mmol) was stirred for 1 hour in EtOAc under air atmosphere.
The reaction mixture was concentrated in vacuo and purified by column
chromatography (15-50% MeOH in CH 2 Cl2) to yield 84 (1.45 g, 98%) as an off-white
solid which can be recrystallized from EtOAc/Hexane.
Physical Data:
1H NMR (300 MHz, DMSO): 8 9.88 (s, 1 H), 7.41 (d, J = 8.4 Hz), 7.25 (d, J = 8.4 Hz),
7.12-7.02 (m, 3 Hz), 7.02-6.95 (m, 1 H), 3.55 (s, 2 H), 3.16 (s, 2 H), 2.78 (t, J = 6.1 Hz,
2 H), 2.64 (t, J = 6.1 Hz, 2 H), 2.33 (t, J = 7.8 Hz, 2 H), 2.26 (t, J = 7.2 Hz, 2 H),
1.79 (quin, J = 7.4 Hz, 2 H)
13C NMR (75.44 MHz, DMSO): 8 173.62, 170.08, 137.63, 134.22, 133.55, 132.23,
128.49, 127.83, 125.76, 125.35, 124.85, 118.41, 60.85, 54.79, 49.57, 34.87, 32.52,
28.10, 19.96
HRMS (M+): Calcld 354.4332 Found 354.4335
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Oxidation of the glutarylamidebenzyl isoquinoline 84 to the N-oxide:
To a stirred solution of 84 (0.446 g, 1.27 mmol) in THF was added 85% m-
CPBA (0.386 g, 1.9 mmol) over 2 minutes. The reaction was complete within 10
minutes and the precipitated product 74 was isolated via filtration, washed with
THF and CH 2 Cl2, and dried to give 74 (0.40 g, 97%) as a white solid.
Physical Data:
1H NMR (300 MHz, DMSO): 8 10.13 (s, 1H), 7.63 (d, J = 8.4 Hz, 2 H), 7.49 (d, J = 8.4
Hz, 2 H), 7.23-7.10 (m, 3 H), 6.98 (d, J = 8.2 Hz, 2 H), 4.64 (s, 3 H), 4.17 (d, 15.1 Hz,
2 H), 3.70-3.54 (m, 3 H), 3.34-3.18 (m, 3 H), 2.32 (t, J = 7.4 Hz, 2 H), 2.23 (t, J = 7.4
Hz, 2 H), 1.83-1.69 (m, 2 H)
13C NMR (75.44 MHz, DMSO): 8 175.52, 171.30, 140.36, 133.37, 131.49, 129.12,
128.08, 127.08, 126.79, 126.21, 123.75, 118.50, 71.02, 67.02, 64.00, 35.80, 34.53,
25.12, 21.01.
HRMS (M+): Calcld 370.4326 Found 368.4323
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The N-hydroxvsuccinamide ester of the glutarylamidobenzyl isoquinoline 84:
To a suspension N-hydroxysuccinamide (0.011 g, 0.094 mmol) in a solution of
84 (0.03 g, 0.085 mmol) and DMAP (cat) in 2 mL of dry CH 2 012 was added EDC
(0.025 g, 0.13 mmol) and stirred for 18 hours. The mixture was washed water. The
organic layer was dried with MgSO4, and concentrated in vacuo. Purification by
column chromatography (5% MeOH in CH2 C12) afforded 84a (0.03 g, 79%) as a
white solid. It can be recrystallized from EtOAc/Et 2 0 for analytical purposes.
Physical Data:
1H NMR (300 MHz, CD 2 Cl2 ): 8 7.96 (s, 1 H), 7.52 (d, J = 8.2 Hz, 2 H), 7.34 (d, J =
8.2 Hz, 2 H), 7.13-7.05 (m, 3 H), 7.01-6.95 (m, 1 H), 3.65 (s, 2 H), 3.60 (s, 2 H), 2.88
(t, J = 5.4 Hz, 2 H), 2.85 (s, 4 H), 2.74 (t, J = 5.4 Hz, 2 H), 2.73 (t, J = 6.9 Hz, 2 H),
2.46 (t, J = 6.9 Hz, 2 H), 2.15 (quin, J = 6.9 Hz, 2 H)
13C0 NMR (75.44 MHz, CD2 C12): 8 170.26, 169.99, 168.93, 137.70, 135.19, 134.81,
134.35, 129.97, 128.96, 126.84, 126.44, 125.86, 120.01, 62.35, 56.47, 35.76, 30.36,
29.35, 26.04, 21.28
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Oxidation of N-hydroxysuccinamide ester of glutarylamido-benzylisoquinoline 84a
to the N-Oxide 74a:
To a stirred solution of 84a (0.105 g, 0.234 mmol) in 10mL of dry CH 2 Cl2 was
added m-CPBA (0.053 g, 0.258 mmol). The reaction was complete after 5 minutes.
The reaction mixture was concentrated in vacuo and purified by flash column
chromatography (5-16% MeOH in CH 2 Cl2) to yield 74a (0.099 g, 91%) as a white
film.
Physical Data:
1H NMR (300 MHz, CD 3 OD): 6 7.67 (d, J = 8.4 Hz, 2 H), 7.52 (d, J = 8.4 Hz, 2 H),
7.29-7.13 (m, 3 H), 6.93 (d, J = 8.0 Hz, 1 H), 4.77-4.52 (m, 3 H), 4.23 (d, J = 14.2 Hz,
1 H), 3.72-3.61 (m, 2 H), 3.33-3.29 (m, 1 H), 2.97 (d, J = 14.2 Hz, 1 H), 2.78 (s, 4 H),
2.74 (t, J = 5.4 Hz, 2 H), 2.49 (t, J = 7.1 Hz, 2 H), 2.10-1.98 (m, 2 H)
13C NMR (75.44 MHz, CD3OD): 8 176.42, 173.12, 171.81, 169.96, 141.67, 134.71,
132.09, 130.22, 129.48, 129.16, 128.98, 128.04, 127.86, 125.00, 120.72, 72.95, 65.49,
61.80, 36.13, 33.93, 30.86, 26.48, 25.62, 21.67
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4.1.3 Synthesis of the Substrate 75
Me 3 AI
Trimethyaluminium assisted ring openning of dihydrocoumarin with p-nitroaniline:
To a stirred suspension ofp-nitroaniline (1.03 g, 7.5 mmol) in 25 mL of
CH 2 C12, was added a 2 M solution of trimethylaluminium in CH 2 C12 (3.8 mL, 7.6
mmol) dropwise. The mixture was stirred for 30 minutes until the gas generation
was complete and it became a deep red color. To this dihydrocoumarin (0.85 mL, 6.8
mmol) was added dropwise and the reaction was stirred for 24 hours, diluted with
50 mL of 1N HC1 and extracted twice with 50 mL of CH 2C012 . The extracts were
combined, dried with MgSO4 , and concentrated in vacuo. Recrystallization from
CH 2 C12 afforded substrate 75 as light yellow crystals (1.42 g, 78%).
Physical Data:
1H NMR (300 MHz, DMSO): 8 10.47 (s, 1 H), 9.32 (s, 1 H), 8.17 (d, J = 8.6 Hz, 2 H),
7.89 (d, J = 8.6 Hz, 2 H), 7.04 (d, J = 7.6 Hz, 2 H), 6.97 (t, J = 7.4 Hz, 2 H), 6.75 (d, J
= 7.6 Hz, 2 H), 6.66 (t, J = 7.4 Hz, 2 H), 2.82 (t, J = 7.8 Hz, 2 H), 2.63 (t, J = 7.8 Hz,
2 H)
13C NMR (75.44 MHz, DMSO): 8 175.48, 145.68, 134.97, 134.56, 129.87, 128.46,
127.18, 126.94, 126.62, 122.17, 118.37, 52.42, 28.54
HRMS (M+): Calcld 270.2879 Found 270.2877
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4.2 Biological Methods
All of the cell culture work including the fusion protocol was performed in a
sterile laminar flow hood, using sterile instruments and upon sterilization of hands
with ethanol. Cells were incubated in a 37 TC sterile incubator containing 90%
humidity and 5% CO 2 (for buffering with carbonate buffer in the cell media).
Development of yellow color indicates the depletion of nutrients in the cell cultures
(generation of acidic pH by metabolites indicated by phenol red in cell medium) and
these cultures should be replenished immediately with the appropriate fresh
medium (pre-warmed to 37 oC). Cells should never be left to stand at room
temperature for longer than 15 minutes and sterile cell containers should only be
opened to the atmosphere under a sterile laminar flow hood. Cell cultures should be
monitored at least daily and those that are observed to be infected should be
discarded immediately to contain the infection.
All biological solutions were stored in sterile containers and at 4 oC unless
otherwise noted. 0.1% Sodium Azide can be added to biological samples to inhibit
bacterial growth when it is not expected to interfere with the ensuing assays.
4.2.1 Preparation of Carrier Protein-Hapten Conjugates
Hapten-protein conjugation reactions were performed at room temperature
with stirring in 5 mL covered vials. Conjugates were exhaustively dialyzed against
0.2 M sodium phosphate buffer (Kpi, pH 7.2) at 40C. Exhaustive dialysis is defined
as a minimum of 106-fold dilution of the sample buffer.
Protein assays were performed according to the method of Bradford using the
Bradford Assay solution (Bio-Rad) diluted 1/4 (v/v) with H20. Pure BSA (Bovine
Serum Albumin) and KLH (Keyhole Limpocet Hemocyanin) were used for the
standard curve. Quantitation of the hapten/protein ratios was determined through
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a comparison of the U.V. spectra of the protein-hapten conjugate, unconjugated
protein and the free hapten.
4.2.1.1 Carrier Protein-72 and -74 Conjugates
To a solution of 5 mg hapten bearing an activated ester in DMF (0.25 mL)
was added carefully 0.25mL of Kpi. This solution was added dropwise to solution of
5 mg carrier protein (BSA or KLH) in 0.5 mL Kpi while swirling. After gentle
stirring for 2 h, the solution was transferred into a dialysis tube (Spectra/Por 2,
molecular cut-off 14,000) and dialyzed twice against 500 mL of Kpi.
4.2.1.2 Carrier Protein-73 Conjugate
To a solution of 5 mg hapten 73 bearing an activated ester in Kpi (0.5 mL)
was added dropwise to solution of 5 mg carrier protein (BSA or KLH) in 0.5mL Kpi
while swirling. After gently stirring for 2 hours the solution was transferred into a
dialysis tube and dialyzed twice against 500 mL of Kpi.
4.2.2 Immunizations
For soluble conjugates 1 mg of Hapten-protein conjugate was diluted with
PBS to a final volume of 2 mL. After transferring this solution into a bottle of RIBI
adjuvant (MPM and TDM emulsion) at room temperature it was vortexed
vigorously for 2-3 minutes to provide an emulsified antigen solution. For
precipitated conjugates, 0.1 mg of hapten-protein conjugate was diluted with PBS to
a final volume of 150 gL and emulsified with 50 gL of Alum (Pierce Biosciences).
100 gL of the emulsions was injected subcutaneously to each side on the back of a
Balb/c mouse using a 1 mL syringe with a 25G 5/8 needle. Fourteen days after the
primary injection a secondary injection was performed according to above
procedure. Twenty-one days after the first injection, the mouse was bled and the
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titer of the serum was estimated by ELISA (section 4.2.3). Intravenous injection was
performed about five weeks after the primary injection using an 29 G 1/2 gauge
needle and was given through a tail vein. The mouse was first warmed to dilate its
blood vessels by shining a heat lamp directly into the open cage (from a distance of
about 1 foot) for 3-5 minutes. The mouse was then removed, placed in a mouse
restraint, and one of the four blood vessels running laterally through the tail was
injected with a solution of 100 gg hapten-protein conjugate in 0.1 mL sterile PBS.
Three days after the last injection the mouse was sacrificed by CO 2 asphyxiation
and the spleen harvested to prepare hybridoma cells.
4.2.3 Enzyme Linked ImmunoSorbent Assay (ELISA)
An ELISA was performed to identify positive hybridoma clones producing IgG
molecules which specifically bind to the hapten. The standard ELISA protocol
requires the following buffers:
Buffer Components
Coating Buffer 0.05 M NaCO3 (pH 9.0)
Washing Buffer PBS: 0.8 g NaC1, 0.2 g KC1,
0.2 g KH2PO4, 1.15 g Na2HPO4
in 1 L dd H20
Blocking Buffer PBS containing 10 gg/ mL
of protein (BSA or Fib)
PBS-Tween PBS containing tween 20
(1:1000 dilution)
Substrate Solution 0.1 M Sodium citrate (pH 5.0)
containing 1,2-phenylenediamine
(4 mg/10 mL) and 30% hydrogen
peroxide (1:1000 dilution).
Each well of a 96-well polyvinyl assay plate (ELISA plate) was coated with
100 gL of the appropriate protein-hapten conjugate (2 p.g/mL) in Coating Buffer and
incubated at 4 'C overnight or at room temperature for 2 hours. The solutions were
discarded by gentle tapping, each well was filled with 200 pL of blocking buffer, and
the plates were allowed to stand at room temperature for 1 hour. The plate was
rinsed with PBS Tween followed by three rinses with distilled water (Washing
Protocol). The hybridoma supernatant from each well of the 96-well cell culture
plates was added to the ELISA plates and incubated for 1 hour, the supernatant
was removed, and the plates were washed according to the washing protocol. Goat
anti-mouse IgG-HRP conjugate, diluted in washing buffer (1:1000 dilution), was
added to each well (100 gL/well) and the plates were allowed to stand at room
temperature for 1 hour. The plates were washed again according to the washing
protocol. Finally, each well was treated with 100 gL of a solution of 1,2-
phenylenediamine (0.4 mg/mL) in 0.1 M sodium citrate (pH 5.0) containing 0.1 %
hydrogen peroxide. The yellow color was allowed to develop for approximately 5
minutes, and the reaction was stopped upon addition of 20 gL of 1.0 M H2SO 4.
Positive clones were identified by measuring the absorbance at 450 nm using a
microtiter plate reader or more simply by visual identification through comparison
with the negative controls.
Titration of antibodies in animal serum was carried out as follows. The
protein-hapten coated ELISA plate was prepared as described above, and to each
well was added 100 gL of PBS. The serum was diluted 200-fold in PBS, and 100 gL
was added to the first well (Al) of the plate. The resulting solution was serially
diluted 2-fold from well Al to well A8 (from 1:400 to 1:51,200 dilution), and the
plate was incubated for 1 hour. The ELISA procedure was then applied as
described above, and the absorbance at 450 nm was measured. A plot of the log of
the serum dilution vs. absorbance provided a sigmoidal curve, and the titer was
defined as the serum dilution at which the absorbance became comparable to that of
the background.
4.2.4 Preperation of media
All tissue culture work was carried out using Dulbecco's modified Eagle's
medium with glucose (DME, Sigma). The following stock solutions of supplements
(sterile filtered) were prepared in a sterile laminar flow hood.
Supplement
O.P.
Glutamine
Gentamicin
8-Azaguanine
Components
1.5 g oxaloacetic acid,
0.5 g pyruvic acid, 100 mL
dd H20, pH 7.4
200 mM in dd H20
50 mg/mL (Sigma)
6.6 x 10-3M (Sigma) in DME
All supplement quantities are per 1L of DME medium.
a) Myeloma Growth Medium (MG-medium):
- 10% Fetal Bovine Serum (FBS)
- 10 mL O.P.
- 20 mL Glutamine
- 3 mL 8-Azaguanine
- 10 mL ITS+ (Collaborative Research)
- 2 mL Gentamicin
b) Serum Free Medium (SF-medium):
- 150 mg Endothelial Cell Growth
-2 mL Gentamicin
Supplement (ECGS, Collaborative Research)
c) Selection Medium (HAT-medium):
- 20% FBS
- 10 mL O.P.
- 20 mL Glutamine
- 10 mL Nonessential amino acids (Sigma)
- 10 mL Hybridoma Enhancing Supplement (HES, Sigma)
- 20 mL Hybridoma Cloning Supplement (HCS, Boehringer)
- 10 mL ITS+
- 2 mL Gentamicin
- 2 vials HAT 50x (Sigma)
d) Recovery Medium (HT-medium):
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- 20% FBS
- 10 mL O.P.
- 20 mL Glutamine
- 10 mL Nonessential amino acids (Sigma)
- 10 mL Hybridoma Enhancing Supplement (HES, Sigma)
- 20 mL Hybridoma Cloning Supplement (HCS, Boehringer)
- 10 mL ITS+
- 2 mL Gentamicin
- 2 vials HAT 50x (Sigma)
e) Hybridoma Expansion Medium (HE-medium):
- 20% FBS
- 10 mL O.P.
- 20 mL Glutamine
- 10 mL Nonessential amino acids (Sigma)
- 10 mL Hybridoma Enhancing Supplement (HES, Sigma)
- 20 mL Hybridoma Cloning Supplement (HCS, Boehringer)
- 10 mL ITS+
- 2 mL Gentamicin
- MITO+ (Collaborative Research)
4.2.5 Preperation of Myeloma cells
A vial with frozen X63Ag8.653 myeloma cells was removed from liquid
nitrogen and immediately thawed at 37 'C in a water bath. The cells were
transferred into a 15 mL centrifuge tube containing 10 mL of prewarmed MG-
medium. After the pelleting of the cells by centrifugation for 5 minutes (400 x G on
a bench-top centrifuge) the supernatant was removed by aspiration and discarded.
The cell-pellet was loosened and resuspended in 10 mL of MG-medium. Again, the
cells were centrifuged and the supernatant discarded. The pellet was loosened by
gentle tapping, suspended in 1 mL of MG-medium and transferred into a T-75 flask
containing 20 mL of MG-medium. The cells should be grown at a cell density
between 0.2 and 1x106 cells/ mL to obtain maximum viability (greater than 95%).
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4.2.6 Determination of Cell Viability
Cell densities were determined by tryphan-blue staining as follows: To a 20
gL aliquot of a thoroughly suspended cell sample in a small glass test tube was
added 20 gL of tryphan-blue stain and the resulting cell suspension was thoroughly
mixed. The cells were slowly pipetted into the sample groove of a clean
hemacytometer until the observation window was completely filled. The
hemacytometer was placed on an inverted phase microscope and the living cells
(absence of blue stain in the interior of the cells) in the four counting grids were
counted, divided by four and multiplied by 1 x 104 (the volume of a counting grid).
This number was then multiplied by two, to account for the tryphan-blue dilution,
to afford the number of cells/ mL.
4.2.7 Fusion
1. An immunized mouse was sacrificed and the fur in the abdominal area was
washed with 95% ethanol. The chest cavity was then cut-open with sterile
instruments and the spleen was removed
2. The spleen was placed in a sterile 50 mL conical tube containing 25 mL of
prewarmed (37 'C) SF-medium.
3. In a sterile laminar-flow hood, the spleen and the media were transferred to a
35 mm tissue culture dish. The spleen was washed by transferring into a fresh
tissue culture dish containing 20 mL of SF-medium. Holes were poked in the spleen
with an 18 1/2 gauge needle and medium was injected to wash out the splenocytes.
The spleen was gently teased between two sterile glass slides to provide a
spleenocyte suspension (approximately 1 x 108 cells).
4. The cells were transferred into a 50 mL sterile centrifuge tube carefully
leaving fatty tissue behind, and centrifuged for 5 minutes at 1100 rpm.
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5. While the cells were being centrifuged, Geys hemolytic medium was made up:
14.5 mL of sterile water was mixed with 4.0 mL of Geys solution A, 1.0 mL of Geys
solution B and 0.5 mL of Geys solution C.*
6. The supernatant was removed by aspiration. The pellet was loosened and re-
suspended in Geys hemolytic medium and left to stand for exactly 5 minutes.
7. While the cells were being treated with Geys hemolytic medium, 2 x 107
myeloma cells were transferred into a conical tube. These were then centrifuged
simultaneously with the hemolyzed spleen cells (1100 rpm, 5 min).
8. After aspiration of the supernatants, the pellets were loosened and re-
suspended in 20 mL of SF-medium. The spleen and myeloma cells were combined
and centrifuged (1100 rpm, 5 min).
9. The supernatant was discarded, the pellet was loosened, and 1 mL of pre-
warmed (37 'C) polyethylene glycol (PEG 1500, Boehringer-Mannheim) was added
with gentle swirling over a period of 1 minute at room temperature.
10. Following the complete addition, the 50 mL tube was sealed and the fusion
mixture was immersed in a 37 'C bath and swirled for 90 seconds.
11. Fusion was ended by the addition of the fusion media to the mixture with
gentle swirling according to the following schedule: 1 mL over a period of 1 minute,
then 3 mL over 1 minute, and finally 20 mL over 1 minute. The centrifuge bottle
was then filled to a final volume of 40 mL with fusion media and allowed to stand
for 10 minutes at room temperature.
12. The mixture was centrifuged for 15 minutes at 1100 rpm, the supernatant
was removed via aspiration, and the pellet was loosened and then resuspended in
100 mL of HAT-medium.
13. Cells were dispensed into ten 96-well sterile plates (100 gL per well) and left
to stand at 37 'C in a CO2 incubator for 7 days. After 7 days, each well was
supplemented with 100 gL of HT-medium
96
14. After the clones became visible under a microscope (after 14 days) ELISA was
performed to identify positive colonies for subcloning section 4.2.3).
*Geys Solution A: 35.0 g NH 4C1
1.85 g KC1
1.50 g Na2HPO4 x 12H 20
0.119 g KH2 PO4
5.0 g Glucose
0.05 g Phenol red
25.0 g Gelatine (Difco)
1000 mL dd H20
Geys Solution B: 4.2 g MgCl2 x 6H 20
1.4 g MgSO4 x 7H 20
3.4 g CaCl 2
100 mL ddH20
Geys Solution C: 5.6 g NaHCO 3
100 mL ddH 20O
4.2.8 Limiting Dilution (Subcloning)
Confluent and ELISA positive wells were subcloned according to the following
procedure: The cells were counted and 5000 viable cells were diluted into 1 mL of
HE-medium. 100 p1 of the dilution were transferred into a tissue culture dish
containing 10 mL of HE-medium (50 cells/mL). 2 mL of this dilution were
transferred into a second tissue culture dish containing 8 mL of HE-medium (10
cells/mL). 2 mL of the resulting dilution were transferred into a third tissue culture
dish containing 6 mL of HE-medium (1 cell/0.4 mL). The most dilute suspension was
dispensed (100 l/well) into the first six rows of a 96-well plate (0.25 cell/well). The
second dilution was put (100 gl/well) into the next four rows (1 cell/well), while the
most concentrated dilution was dispensed (100 pl/well) into the remaining two rows
(5 cells/well). After seven days, each well was supplemented with 100 p1 of HE-
medium. Typically, after 14 days ELISA could be performed. Above procedure was
repeated until all wells containing a colony were positive by ELISA (proof of
monoclonality).
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4.2.9 Cryogenic Storage of Cell Lines
Each monoclonal cell line was frozen according to the following protocol. A
healthy cell line (viability > 95%) was grown in 10 mL of HE-medium in a T-15
tissue culture flask to a final density of 1 x 106 cells/ mL. The cells were transferred
into a 10 mL centrifuge tube, and centrifuged for 5 minutes at 1100 rpm. The
supernatant was removed by aspiration and the pellet was re-suspended in 1 mL of
pre-warmed freezing solution (8% DMSO, 92% FBS). The resulting suspension was
then aliquoted between four freezing vials (250 gL/vial) and placed in ice for 1 hour.
The vials were then placed in a styrofoam container leaving the outermost rows
empty to insure gradual cooling and were placed in a -78 oC freezer. Cell lines can
be transferred to a liquid nitrogen storage container for long-term storage no sooner
than 1 week after the initial freezing.
4.2.10 Ascites Production From Monoclonal Hybridomas
In order to generate large quantities of monoclonal antibodies, cell lines were
propagated in vivo in pristane primed mice. Balb/c mice (retired breeders) were
intraperitonally injected with pristane (0.5 mL per mouse) at least 10 days prior to
the injection of hybridoma cell lines. Each monoclonal hybridoma cell line was
individually prepared for injection into a mouse by growing the healthy cell line
(viability > 95%) in 10 mL of HE-medium in a T-15 tissue culture flask to a final
density of 1 x 106 cells/mL. A volume containing 1.5 x 106 cells were transferred
into a 10 mL conical tube and centrifuged for 5 minutes at 1100 rpm. The
supernatant was removed by aspiration, the pellet was resuspended in 0.5 mL of
sterile PBS, and the suspension was injected intraperitoneally into a pristane
primed mouse. Only one monoclonal hybridoma cell line was injected per mouse.
Within one to two weeks, abdominal swelling was generally observed in the injected
mice. Each mouse was "tapped" for the ascites fluid by draining the swelled
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abdominal area into a sterile tube using an 18-gauge needle. It is important that
only the tip of the needle is inserted and penetration of underlying organs is
avoided. Mice were tapped 1-3 times (depending on their health) prior to being
sacrificed.
4.2.11 Purification of Monoclonal Antibodies
Monoclonal antibodies were purified in three steps from the ascites fluid
according to the following protocol. Freshly collected ascites fluid was centrifuged at
3000 rpm for 20 minutes at 4 0C to pellet red blood cells. The supernatant was
collected and an equal volume of saturated ammonium sulfate was added dropwise
with stirring at 4 0C to selectively precipitate the antibodies (with some other large
molecular weight proteins). The samples were allowed to stand overnight at 4 oC
and then were centrifuged at 8000 rpm for 20 minutes. The supernatant was
discarded and the precipitates were solubilized in and exhaustively dialyzed against
50 mM Tris *HC1 (pH 7.8) at 4 'C. Dialyzed samples were centrifuged at 20,000 rpm
for 20 minutes and then filtered through a 0.22 gm low protein binding syringe
filter (Millipore). Each antibody solution was individually loaded onto a DEAE-
Sephacel anion-exchange column (XK26) attached to a Pharmacia FPLC at 4 0C. A
salt gradient (from 0 mM to 500 mM NaCl in 50 mM Tris* HC1, pH 7.8) served to
elute partially purified antibodies. The elution program was as follows: 0-45 mL (0
mM NaC1), 45-46 mL (50 mM NaC1), 46-85 mL (50 mM NaC1), 85-170 mL (150 mM
NaC1), 165-166 mL (500 mM NaC1), 166-205 mL (500 mM NaC1), 205-206 mL (0 mM
NaC1), 206-260 mL (0 mM NaC1) at a rate of 2 mL/min, collecting 10 mL fractions.
Antibody containing fractions were collected (typically between fraction 16 and 22),
concentrated using AMICON filtration apparatus (YM-100 membranes, 10 psi
pressure) to a final volume of approximately 10 mL, and exhaustively dialyzed
against 20 mM Kpi (pH 7.2) at 4 0C in dialysis tubes.
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Samples were filtered through a 0.22 gm syringe filter and loaded onto a
protein G-Sepharose affinity column (HR 16/5) attached to a Pharmacia FPLC at 4
oC. A low pH buffer (100 mM glycine *HC1, pH 2.7) was used to elute pure antibody
(>95%) from the affinity column (equilibrated with 20 mM Kpi at pH 7.2). Antibody
containing fractions were immediately neutralized with 1 M Tris* HC1 (pH 9) and
buffered with 1 M Kpi (pH 7.2). The elution program was as follows: 0-100 mL (0
mM glycine), 100-101 mL (100 mM glycine), 101-160 mL (100 mM glycine), 160-161
mL (0 mM glycine), 161-220 mL (0 mM glycine) at a rate of 2 mL/min, collecting 6
mL fractions. Antibody concentrations were determined using the absorbance at
280 nm and an extinction coefficient of 1.35. Each antibody solution was
concentrated to a working concentration of 6 mg/mL in PIPES-buffer (10 mM, 80
gM NaC1, 0.1% NaN 3, pH 6.8) using AMICON Centriprep 100 concentrators for
buffer exchange and concentration.
4.2.12 Assays for Catalysis
Preliminary assays for catalysis were performed at pH 6.8 (50 mM PIPES, 80
gM NaC1) and at pH 9.0 (50 mM CHES, 80 gM NaC1). Each assay contained 10%
DMSO as organic co-solvent. A 200 gL reaction mixture contained the following: 1
mM amide 75, 10 gM Antibody, 50 gM 4-phenylazophenol as Internal Standard
Calibrant (ISTD). Typically reaction mixtures were made from a 10 fold
concentrated stock solution (10 mM 75, 0.5 mM ISTD in DMSO). Stock solutions
with appropriate dilutions were made in the beginning of the catalytic assays and
were stored frozen at 4 'C. The same stock solutions were used throughout all of
the assays for consistency. Reactions were initiated with the addition of the
appropriate volume of concentrated antibody solution (6 mg/mL) to a pre-mixture of
75, ISTD and buffer (and inhibitor where appropriate). Reactions were assayed at
room temperature over 3 days.
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The reactions were followed at 382 nm (absorption maxima for p -nitroaniline)
in a RAININ UV-D spectophotometer (an absorption peak area of 3120 was
calibrated to correspond to 1 gM p-nitroaniline release with a 20 gL sample
volume). The reaction components were separated using a Waters Nova-Pak C8
column ( 150 mm length x 3.9 mm i.d.) attached to a Rainin HPLC system. 45%
AcN, 0.1% trifluoroacetic acid in ddH20 was used as an isocratic eluent at 1.7
mL/min flow rate. The elution times of the observed species is as follows: p-
nitroaniline 1.33 min., amide 75 1.92 min., 4-phenylazophenol 2.55 min. Typically
spectra were recorded for 4 minutes. Integration of the peaks were performed using
the dedicated Rainin Dynamax computer program run in Apple Macintosh
computers.
Assays for the bi-molecular reactions were done similar to the above except a
35% AcN, 0.1% trifluoroacetic acid in ddH20 isocratic eluent was used at 2.0 mL
flow rate. The elution times of the observed species was as follows: p-nitroaniline
1.62 min., amide 87 2.03 min., 4-phenylazophenol 5.71 min. Typically spectra were
recorded for 7 minutes. Generally 40 gL reaction volumes were assayed over 6 days
with 10 gL sample volumes. Reactions contained 10% DMSO and 5% AcN as
organic co-solvents. Amide 77 stock solutions were made at 20x concentration
including 0.5 mM ISTD in a 1:1 DMSO/AcN mixture. 20x concentrated phenol
solutions were made in DMSO. All stock solutions were made at the beginning of
the assays and used through-out for consistency. Stock solutions were stored frozen
at 4 'C. Reactions were initiated upon addition of the appropriate volume of the
antibody solution (6 mg/mL) to a pre-mixture of 77, Phenol, ISTD and buffer (also
inhibitors where appropriate).
All measurements were done in triplicate. Kinetic plots were determined
using KaleidaGraph program (SYNERGY Software) for Apple Macintosh computers.
101
Biographical Note
The author, Oguz Ersoy, was born in Istanbul, Turkey on February 23, 1968
to parents Dr. QlkUi Ersoy (mother) and Suphi Ersoy (father). He was raised in the
same city and graduated from Istanbul Robert College high-school in 1986. To his
good fortune, in March 14, 1978, his brother Burak Ersoy was born. After attending
the medical school of Marmara University, Istanbul in 1986-87, the author enrolled
in Bates College, where he studied under the tutelage of professors Joseph G.
Pellicia (biology) and David B. Ledlie (chemistry). In the summer of 1988, the
author worked as an undergraduate research fellow at California Institute of
Technology with Dr. Kai Zinn. In 1990, he graduated cum laude from Bates
College, B.S. biology and chemistry, with honors in chemistry. He was also awarded
memberships to Phi Beta Kappa and Phi Lambda Upsilon honorary societies, as
well as receiving the Merck Index Award. In September 1990, he enrolled in MIT,
and soon after began conducting research under the supervision of Professor Satoru
Masamune on catalytic antibodies. Upon the completion of his Sc.D., the author
will travel to Stockholm, Sweden to work as a research scientist at the Karolinska
Institute.
102
References
1Thomas, J. M.; Zamaraev, K. I. eds. Perspectives in Catalysis 1992, Blackwell Scientific
Publications, Oxford.
2Ko, S.Y.; Lee, A.W.M.; Masamune, S.; Reed, L.A.; Sharpless, K.B.; Walker, F.J. Science, 1983,220,
949.
3Ojima, I. ed. Catalytic Asymmetric Synthesis 1993, VCH Publishers, New York.
4 a) Pauling, L. Chem. Eng. News, 1946, 24, 1375. b) Pauling, L. Am. Sci., 1948, 36, 51.
5Jencks, W.P. Catalysis in Chemistry and Enzymology , 1969, McGraw Hill, New York, p.288 .
6a) Raso, V.; Stollar, B.D. J. Am. Chem. Soc., 1973, 95, 162; b) ibid. Biochemistry, 1975, 14, 584;
c)ibid. 591.
7Kohler, G.; Milstein, C. Nature, 1975,256, 495.
8Lerner, R.A. Adv. Immunol. 1984,36, 1.
9 Bartlett, P.A. and Marlowe, C.K. Biochemistry 1983,22, 4618.
10Tramontano, A.; Janda, K.D.; Lerner, R.A. Proc. Natl. Acad. Sci., USA 1986,83, 6736.
11Tramontano, A.; Janda, K.D.; Lerner, R.A. Science, 1986, 234, 1566.
12Pollack, S.J.; Jacobs, J.W.; Schultz, P.G. Science, 1986,234, 1570.
13for example see: Jacobs, J.W.; Schultz, P.G.; Sugasawara, R.; Powell, M. J. Am. Chem. Soc., 1987,
109, 2174; Napper, A.D.; Benkovic, S.J.; Tramontano, A.; Lerner, R.A. Science, 1987,237, 1041;
Benkovic, S.J.; Napper, A.D.; Lerner, R.A. Proc. Natl. Acad. Sci., USA 1988, 85, 5355; Janda, K.D.;
Schloeder, D.; Benkovic, S.J.; Lerner, R.A. Science, 1988,241, 1188; Janda, K.D.; Lerner, R.A.;
Tramontano, A. J. Am. Chem. Soc., 1988, 110, 4835.
14 a) Hilvert, D.; Carpenter, S.H.; Nared, K.D.; Auditor, M-T M. Proc. Natl. Acad. Sci., USA 1988, 85,
4953; b)Hilvert, D.; Nared, K.D. J. Am. Chem. Soc., 1988, 110, 5593; c) Jackson, D.Y.; Jacobs, J.W.;
Sugasawara, R.; Reich, S.H.; Bartlett, P.A.; Schultz, P.G. J. Am. Chem. Soc., 1988,110, 4841.
15Shokat, K.M.; Leumann, C.L.; Sugasawara, R.; Schultz, P.G. Nature, 1989,338, 269.
16 Sheriff, S.; Silverton, E.W.; Padlan, E.A.; Cohen, G.H.; Smith-Gill, S.J.; Finzel, B.C.; Davies, D.R.
Proc. Natl. Acad. Sci., USA 1987, 84, 8075.
17Lerner. R.A.; Benkovic, S.J. BioEssays, 1988, 9, 107.
18Ersoy, O.; Williams, S.F.; Masamune, S. unpublished results.
19a)Lerner, R.A.; Benkovic, S.J.; Schultz, P.G. Science 1991,252, 659. b) Acc. Chem. Res. 1993, vol. 8.
20Iwabuchi, Y.; Miyashita, H.; Tanimura, R.; Kinoshita, K.; Kikuchi, M.; Fujii, I. J. Am. Chem. Soc.
1994, 116, 771.
21Napper, A.D.; Benkovic, S.J.; Tramontano, A.; Lerner, R.A. Science 1987,237, 1041.
2 2Benkovic, S. J.; Napper, A. D.; Lerner, R. A. Proc. Natl. Acad. Sci. USA 1988, 85, 5355.
23 Ikeda, S.; Weinhouse, M. I.; Janda, K. D.; Lerner, R. A.; Danishefskey, S. J. J. Am. Chem. Soc.
1991, 113, 7763.
24Janda, K. D.; Benkovic, S. J.; Lerner, R. A. Science 1989, 244, 437.
2 5Janda, K.D., Ashley, J.A., Jones, T.M., McLeod, D.A., Schloeder, D.M. and Weinhouse, M.I. J. Am.
Chem. Soc. 1990, 112, 8886.
26Wirsching, P.; Ashley, J. A.; Benkovic, S. J.; Janda, K. D.; Lerner, R. A. Science 1991,252, 680.
2 7 Landry, D. W.; Zhao, K.; Yang, G. X.-Q.; Glickman, M.; Georgiadis, T. M. Science 1993,259, 1899.
2 8Kurokawa, T.; Iwasa, S.; Kakinuma, A. Biol/Technology 1989, 7, 1163.
29 Miyashita, H.; Karaki, Y.; Kikuchi, M.; Fujii, I. Proc. Natl. Acac. Sci. USA 1993, 90, 5337.
3 0Campbell, D.A.; Gong, B.; Kochersperger, L.M.; Yonkovich, S.; Gallop, M.A.; Schultz, P.G. J. Am.
Chem. Soc. 1994, 116, 2165.
3 1Janda, K. D.; Schloeder, D.; Benkovic, S. J.; Lerner, R. A. Science 1988, 241, 1188.
3 2Chen, Y.-C. J.; Danon, T.; Sastry, L.; Mubaraki, M.; Janda, K. D.; Lerner, R. A. J. Am. Chem. Soc.
1993, 115, 357.
33 Gibbs, R.A., Taylor, S. and Benkovic, S.J. Science 1992,258, 803-805.
103
34a) Liotta, L.J.; Benkovic, P.A.; Miller, G.A.; Benkovic, S.J. J. Am. Chem. Soc. 1993, 115, 350. b)
Liotta, L.J.; Gibbs, R.A.; Taylor, S.D.; Benkovic, P.A.; Benkovic, S.J. J. Am. Chem. Soc. 1995, 117,
4729.
35Martin, M.T.; Angeles, T.S.; Sugasawara, R.; Aman, N.I.; Napper, A.D; Darsley, M.J.; Sanchez,
R.I.; Booth, P.; Titmas, R.C. J. Am. Chem. Soc. 1994, 116, 6508.
36(a) Janda, K. D.; Weinhouse, M. I.; Schloeder, D. M.; Lerner, R. A.; Benkovic, S. J. J. Am. Chem.
Soc. 1990, 112, 1274.
37Janda, K. D.; Weinhouse, M. I.; Danon, T.; Pacelli, K. A.; Schloeder, D. M. Ibid. 1991,113, 5427.
38A significant amount of the actual experimental work that is discussed within this section has
been performed by the author in the second and third years of his tenure as a graduate student. As a
detailed discussion of this work has already been presented in the Ph.D. dissertation of Dr. Hiroaki
Suga (MIT Dept. of Chemistry, 1994) as well as published (see ref. 49) only a brief summary will be
offered here.
39Suga, H.; Ersoy, O.; Tsumuraya, T.; Lee, J.; Sinskey, A.J., Masamune, S. J. Am. Chem. Soc., 1994,
116,487.
4 0Suga, H.; Ersoy, O., Masamune, S. unpublished results.
41 Iverson, B. L.; Lerner, R. A. Science 1989, 243, 1184.
42Blackburn, G.M.; Deng, S.-X. Biochem. Soc. Trans. 1994,21, 1102.
43Se11, S. Basic Immunology, 1987, Elsevier, New York, p. 199-234.
44Francis, R. Jr. Ann. Intern. Med. 1953, 39, 203.
45 a)Fazekas de St. Groth S.; Webster, R. G. J. Exp. Med. 1966, 124, 347. b) Levin, H. A.; Herman, J.;
Levine, H.; Schlossman, S. F. J. Immunol. 1972,108, 538.
4 6 Deutsch S.; Bussard, A. E. Eur. J. Immunol. 1972,2, 374.
4 7Fish, S.; Zenowich, E.; Fleming, M.; Manser, T. J. Exp. Med. 1989, 170, 1191.
48Manser, T, Wysocki, L. J.; Margolies, M. N.; Gefter, M. L. Immunol. Rev. 1987, 96, 141.
4 9a)Suga, H.; Ersoy, O.; Williams, S.F.; Tsumuraya, T.; Margolies, M.N.; Sinskey, A.J., Masamune,
S. J. Am. Chem. Soc., 1994, 116, 6025. b)Suga, H.; Ersoy, O.; Williams, S.F.; Tsumuraya, T.;
Margolies, M.N.; Sinskey, A.J., Masamune, S. J. Am. Chem. Soc., 1994, 116, 8432. c)Tsumuraya, T.;
Suga, H.; Meguro, S.; Tsukanawa, A.; Masamune, S. J. Am. Chem. Soc., 1995, 117, 11390.
50Page, M.I.; Williams, A. Eds. Enzyme Mechanisms The Royal Society of Chemistry, London, 1987
51Benkovic, S. J.; Adams, J. A.; Borders Jr., C. L.; Janda, K. D.; Lerner, R. A. Science 1990,250,
1135.
52Janda, K.D., Ashley, J.A., Jones, T.M., McLeod, D.A., Schloeder, D.M., Weinhouse, M.I., Lerner,
R.A., Gibbs, R.A., Benkovic, P.A., Hilhorst, R. and Benkovic, S.J. J. Am. Chem. Soc.1991, 113, 291.
53Gibbs, R. A.; Benkovic, P. A.; Janda, K. D.; Lerner, R. A.; Benkovic, S. J. J. Am. Chem. Soc. 1992,
114, 3528.
54a) Stewart, J.D.; Krebs, J.F.; Siuzdak, G.; Berdis, A.J.; Smithrud, D.B.; Benkovic, S.J. Proc. Natl.
Acad. Sci. USA, 1994, 91, 7404. b) Stewart, J.D.; Roberts, V.A.; Thomas, N.R.; Getzoff, E.D.;
Benkovic, S.J. Biochemistry 1994,33, 1994.
55Siuzdak, G.;Krebs, J.F.; Benkovic, S.J.; Dyson, H.J. J. Am. Chem. Soc.1994, 116, 7937.
56Martin, M. T.; Napper, A. D.; Schultz, P. G.; Ress, A. R. Biochemistry 1991, 30, 9757.
57Guo, J.; Wei, H.; Scanlan, T.S. J. Am. Chem. Soc.1994, 116,6062.
58Zhou, G.W.; Guo, J; Wei, H.; Fletterick, R.J.; Scanlan, T.S. Science, 1994,265, 1059.
59Guo, J; Wei, H.; Zhou, G.W.; Fletterick, R.J.; Scanlan, T.S. Proc. Natl. Acad. Sci. USA, 1995,92,
1694.
60a)Baldwin, E.; Schultz, P.G. Science 1989,245, 1104. b)Jackson; D.Y., Prudent; J.R., Baldwin,
E.P.; Schultz, P.G. Proc. Natl. Acad. Sci. USA 1991, 88, 58. c)Wade, W.S.; Koh, J.S.; Han, N.;
Hoekstra, D.M.; Lerner, R.A. J. Am. Chem. Soc. 1993, 115, 4449. d)Crowder, M.W.; Stewart, J.D.;
Roberts, V.A.; Bender, C.J.; Tevelrakh, E.; Peisach, J.; Getzoff, E.D.; Gaffney, B.J.; Benkovic, S.J. J.
Am. Chem. Soc. 1995, 117, 5627.
104
6 1This work was done in collaboration with Mr. Roman Fleck, and the relevant parts of this work,
esp. the syntheses of hapten 73 and substrate 77 will be reported in the dissertation thesis of this
author.
62Huval, C.; Masamune, S. umpublished results
63Mikolajczyk, M.; Grzejszczak, G.; Midura, W.; Zatorski, A. Synthesis 1976, 396.
64This background rate is in accordance with a previously determined background rate for a similar
p-nitroanilide substrate, see: Janda, K. D.; Schloeder, D.; Benkovic, S. J.; Lerner, R. A. Science 1988,
241, 1188.
65a)Tawfik, D.S.; Green, B.S.; Chap, R.; Sela, R.; Eshhar, Z. Proc. Natl. Acad. Sci. USA 1993,90, 373.
b) MacBeath, G.; Hilvert, D. J. Am. Chem. Soc. 1994, 116, 6101.
66Schmidhammer, H.; Brossi, A. J. Org. Chem. 1983,48, 1469.
105
